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Abstract 
Alphaherpesvirus infections in the central nervous system (CNS) are rare 
but severe, and many patients show remaining neurological sequelae. While 
antiviral treatment has reduced the mortality, morbidity has not been 
diminished to the same degree, and the immune system activation might 
contribute to the pathogenesis. Clinical symptoms have often been in focus 
in previous studies of such infections, while the entry and spread of viral 
agents is less thoroughly elucidated. Therefore, the aim of this thesis was to 
investigate aspects of the pathogenesis of herpes simplex virus type 1 (HSV-
1) infections in the CNS, including viral properties related to virulence, 
transport and tropism, and to host immune responses in this compartment. 
Infection in a rodent model of herpes simplex encephalitis (HSE) 
revealed that HSV-1 can enter the brain via the trigeminal nerve or the 
olfactory bulb. Furthermore, HSV-1 was found to utilize the anterior 
commissure (AC), a bundle of nerve fibres between the two brain 
hemispheres, for transport to the contralateral hemisphere. In the AC, HSV-
1 targeted cells morphologically resembling oligodendrocytes, which could 
suggest that virus may utilize additional cells to neurons for rapid transport. 
Cerebrospinal fluid (CSF) samples from HSE patients and controls were 
analysed for concentrations of CNS aquaporins (water channels) and 
complement components participating in the innate immune response. 
Increased concentrations were found in HSE patients for aquaporin 9 
(AQP9) and complement components C3a, C3b, C5 and C5a as compared 
with healthy controls, indicative of an increased intrathecal immune activity 
in HSE. For C3a and C5a, the activity was increased both in acute and 
convalescent stages of HSE, further contributing to previous observations of 
increased immune activity in convalescence. 
In a cell culture model for differentiation of induced pluripotent stem 
cells into cortical neurons, reflecting neuronal development, the 
susceptibility of differentiating cells to infection with HSV-1 or herpes 
simplex virus type 2 (HSV-2) was investigated. Despite production of high 
viral titres and high viral DNA quantities both early and late in 
differentiation, the cell viability of cells in late differentiation was higher 
than for cells in early differentiation. Thus, neuronal progenitor cells were 
more vulnerable to infection than mature cortical neurons. 
The role of the mucin-like region of glycoprotein C of HSV-1 was 
studied in cell culture and surface binding resonance experiments. Here it 
was found that the mucin-like region facilitated both viral attachment to cell 
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surface glycosaminoglycans upon infection and, more importantly, to egress 
and release of newly produced virions from infected cells. 
Altogether, the findings in this thesis supported previous findings of viral 
and immunological factors contributing to the CNS infectivity and outcome 
in HSE. In addition, a novel pathway for HSV-1 transport in the brain in 
form of AC was discovered. Finally, the importance of the complement 
system activation in the CNS in HSE patients, and a role for mucin-like 
region of gC in HSV-1 attachment and egress in vitro was demonstrated. 
Keywords: herpes simplex virus; herpes simplex encephalitis; central 
nervous system infection; complement system; aquaporin 9; glycoprotein 
C; differentiating neuronal cells; mucin-like region 
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Sammanfattning på svenska 
Alfaherpesvirus är en grupp virus som vid infektion inte försvinner ur 
kroppen utan istället stannar kvar hela livet. Till dessa virus hör herpes 
simplexvirus typ 1 (HSV-1) som oftast ses vid munsår, herpes simplexvirus 
typ 2 (HSV-2) som vanligen ses vid könsherpes och varicella-zostervirus 
(VZV) som orsakar vattkoppor och bältros. Även om de synliga symtomen 
vid aktiv virusinfektion involverar hud och slemhinnor, kan dessa virus 
infektera även andra celler och vävnader i kroppen. Exempelvis infekterar 
alfaherpesvirus känselnervernas nervknutor (ganglier) belägna utmed 
ryggraden där de återfinns i ett viloliknande stadium, så kallad latensfas, 
under långa perioder. Hos vissa människor kan dessa virus periodvis 
aktiveras för att åter ge symptom. 
Vanligtvis är alfaherpesvirusinfektioner milda, men i ovanliga fall kan de 
sprida sig till centrala nervsystemet (CNS), upp till hjärnan, där utgången 
kan bli mycket allvarlig. Beroende på vilken del av hjärnan som infekteras 
kan infektionen leda till döden, speciellt om den inte behandlas med 
läkemedel i tid. Även om infektionen behandlas kan dock många få 
bestående skador i form av epileptiska anfall, minnessvårigheter, och 
problem med att hantera känslointryck. Medan HSV-1 kan orsaka det svåra 
tillståndet hjärninflammation (encefalit) hos vuxna, leder HSV-2 infektion 
ofta till virusorsakad hjärnhinneinflammation (meningit) som är mycket 
lindrigare. Hos nyfödda barn är däremot HSV-2-infektion i hjärnan 
allvarligare än HSV-1-infektion. Mycket är känt om de olika symptom och 
skador man ser i samband med herpesinfektioner i hjärnan, men man vet 
desto mindre om varför dessa komplikationer uppstår och hur HSV-1 tar sig 
till och infekterar en specifik del av hjärnan. 
Runt området kring näsa och mun finns två stora nerver som kan 
signalera till hjärnan: luktnerven och trilling- (trigeminus-) nerven. HSV-1 
kan utnyttja dessa nerver för att ta sig in i hjärnan och sedan spridas till det 
område som infekteras. Genom att infektera råttor med HSV-1 i näsborren 
och sedan följa infektionen, kunde vi se att efter att infektionen etablerat sig 
i luktloben i ena hjärnhalvan så spred sig viruset snabbt till den andra 
luktloben genom att utnyttja ett utvecklingsmässigt uråldrigt signalerings-
system, den främre kommissuren, mellan de två hjärnhalvorna.  
En orsak till de bestående skador man ser efter infektioner i hjärnan kan 
vara att det egna immunförsvaret attackerar infekterade celler. För att testa 
aktiviteten för en komponent av det medfödda immunförsvaret, 
komplementsystemet, mätte vi flera av dess faktorer i ryggmärgsvätska och 
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jämförde med nivåerna i blodet. Till skillnad från friska kontroller fann vi 
att komplementsystemets aktivitet var hög i CNS hos patienter med 
herpesencefalit, även lång tid efter att virusinfektionen läkt ut. Den ökade 
komplementaktiviteten bekräftade att immunförsvaret kan påverka förloppet 
vid encefalit, och vid sidan om läkemedel mot herpesvirus kan dessa 
patienter även tillfälligt behöva läkemedel som dämpar immunförsvaret. 
För att studera likheter och skillnader i infektion av nervceller mellan 
HSV-1 och HSV-2 använde vi oss av en cellmodell där cellerna undersöktes 
under olika utvecklingsgrad. Försöksresultaten visade att när det inte finns 
immunceller närvarande är delande nervceller under utveckling mycket 
känsligare för virusinfektion än mogna, icke-delande nervceller. 
Slutligen studerade vi hur ett specifikt protein som sitter på virushöljet, 
glykoprotein C (gC), kan binda till konstgjorda membraner och påverka 
HSV-1-infektion av celler. Ett område på proteinet med många 
sockermolekyler, en så kallad mucindomän, gynnade bindning både av gC 
och av hela viruspartiklar, till en virusreceptor i form av kondroitinsulfat. Ett 
viktigt fynd var också att mucindomänen på gC underlättade för nybildade 
virus att lämna sin värdcell. 
Sammanfattningsvis visar studierna i denna avhandling på att förloppet 
av herpesvirusinfektioner i hjärnan inte enbart beror på en enda faktor, utan 
att flera egenskaper både hos virus, nervceller och immunförsvar samverkar 
och avgör hur allvarlig infektionen blir.  
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1 .  AIM S 1 
1. Aims 
The overall aim of this thesis was to investigate aspects of the pathogenesis of 
herpes simplex virus type 1 (HSV-1) infections in the central nervous system 
(CNS), through studies in cell cultures, animal experiments and clinical studies. 
The studies included those on viral properties related to virulence, transport and 
tropism, and of host responses to such viral infection.  
Specific aims: 
- To investigate the spread of HSV-1 within the CNS after olfactory 
infection in a rat model, with emphasis on involvement of specific 
neuroanatomical structures and connections. 
 
- To assess whether the complement system is activated systemically 
and/or intrathecally in herpes simplex encephalitis (HSE) and, if so, to 
determine its route of activation and the duration of this immune response 
in the patients. 
 
To investigate, in a cell culture model differentiating towards human 
cortical neurons, if neuronal differentiation affects the viral replication 
and cytopathogenicity during HSV-1 (and HSV-2) infection.  
 
- To define a role for the mucin-like region of HSV-1 glycoprotein C (gC) 
for attachment to the viral receptor of glycosaminoglycan (GAG) nature 
during viral entry and release from the same binding during egress, 
functions that may be decisive for tropism and transport of this virus.  
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2 .  INTR ODUC TION 3 
2. Introduction 
Viruses are so-called obligate intracellular parasites. Lacking a functioning cell 
machinery, viruses require a living host cell for replication and protein synthesis. 
Cells from all living organisms can be infected by viruses; animals, plants, fungi, 
bacteria, but the families of infecting viruses are usually specific for their 
respective host organism [1].  
In animals, viruses infect by breaking through the existing natural protective 
barriers of the body. Once inside, viruses normally evade the immune control and 
thereby cause disease, either by killing cells or by triggering a destructive immune 
and inflammatory response.  
After infection, viruses display a tropism for specific tissues, which means that 
they preferably infect tissues and cells to which they are adapted. Some viruses 
show a broad tropism and can infect many different tissues, while other viruses 
present with narrow tropism and can only infect specific cell types. Once inside 
the host, the viral infection has three potential outcomes [2]: abortive (failed) 
infection, lytic infection, with cell death as a result, or persistent infection, where 
cells are infected but not subjected to cell death. Persistent infections can be 
subdivided into chronic latent infections or transforming infections. Chronic latent 
infections are non-lytic with restricted transcription of viral genes; no complete 
viral particles are synthesized unless the host cell is exposed to stress or other 
stimuli that may reactivate the infection. Transforming infections result in 
immortalisation or transformation of the host cell [2].  
Susceptibility and severity of an infection may in part be determined by the 
functional capacity of the immune response [3]. Immunosuppression, and thereby 
reduced activity or efficacy of the immune response, can certainly be a negative 
determinant of how the infection is resolved and how severe the outcome of the 
symptoms will be (reviewed in [4]). However, although immunosuppressed 
patients are at a greater risk of more severe course of a primary infection and are 
more prone to experience recurrent infections after reactivation from latency of 
certain viruses, other factors may also be of importance for the outcome of the 
infection. Specific age groups, such as young children and the elderly, are more at 
risk for being infected by certain viruses, and the severity of the infection may 
also be increased [5]. Moreover, genetic alterations related to the virus and to the 
host can affect the course of the infection, as can the viral exposure dose, 
geographic restrictions and seasonal variations. A viral mutation can result in 
either reduced or increased infectivity, and could also influence the outcome [6-
17]. Similarly, a mutation in the host can increase or reduce the risk for viral 
infection when genes coding for viral receptors are targeted, and alterations in 
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genes responsible for immune functions can be decisive for the outcome of the 
infection [18-20]. All viruses have, just as all other organisms, an ecologic niche 
and prefer a certain climate and temperature for spread and infection (reviewed in 
[21]). Connected to this are seasonal variations in infectivity, and some viral 
infections are more prevalent during the winter, when temperature drops, humidity 
might decrease and people may gather inside in larger groups [5]. Other viruses 
are more prevalent during the summer when increased temperatures favour water- 
and food hygiene-related spread and enable spread of viral vectors such as 
mosquitos and ticks [5].  
Viruses are transmitted between hosts through different mechanisms. Some 
viruses are airborne and travel via aerosols, others via faecal-oral transmission, 
some via direct contact (with lesions, saliva, breast milk etc.) or indirect contact 
(contaminated objects, water, food) [5]. Furthermore, some viruses can be 
transmitted as zoonoses (animals or insects are vectors or reservoirs), others via 
blood transfusions, or through sexual contacts, and vertically from mother to child 
congenitally or during delivery [5]. 
2.1 Herpesviridae 
Herpesviridae, the herpesvirus family, consists of large enveloped DNA 
viruses that cause latent and/or lytic infection in hosts throughout the animal 
kingdom [22]. Because of their envelope, herpesviruses are sensitive to acids, 
detergents and drying and therefore often spread via close contact (although some 
are airborne). The name herpes is derived from a Greek word, Herpein, meaning 
“to creep”, referring to the creeping skin eruption of zoster and oral/genital 
herpetic lesions.  
To date, there are three known subfamilies of the mammalian herpesviridae, 
divided according to the biological properties and site of latency of the viruses. 
Viruses infecting humans are represented in all subfamilies [23]: 
- Alphaherpesviruses  
o Herpes simplex virus type 1 (HSV-1) 
o Herpes simplex virus type 2 (HSV-2) 
o Varicella zoster virus (VZV) 
- Betaherpesviruses 
o Cytomegalovirus (CMV) 
o Human herpesvirus 6A (HHV-6A) 
o Human herpesvirus 6B (HHV-6B) 
o Human herpesvirus 7 (HHV-7) 
- Gammaherpesviruses 
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o Epstein-Barr virus (EBV) 
o Kaposi’s sarcoma-associated herpesvirus (KSHV) 
Alphaherpesviruses 
Alphaherpesviruses have a wide tropism as they can infect most cells and 
organs in the body and often cause an initial viraemia during the primary infection. 
However, thereafter they specifically target mucoepithelial cells (fibroblasts and 
epithelial cells) where they cause lytic infections, and establish latency in sensory 
neurons from which they can reactivate to cause recurrent mucoepithelial lesions 
[23]. Other features of the alphaherpesviruses are relatively short reproductive 
cycles, fast progression of infection in cultured cells and lytic effect on infected 
cells where the virus is not harboured latently [22]. 
As presented above, the human alphaherpesviruses include HSV-1, HSV-2 and 
VZV. HSV-1 and 2 cause mucoepithelial lesions of the oral area (more common 
for HSV-1) or the genital area (more common for HSV-2) while VZV causes 
chickenpox (varicella, lesions all over the body) and shingles (zoster, lesions 
limited to a dermatome). Other types of infections can also occur, where some are 
more severe, including eye infection (keratitis) [24], hepatitis [25-27], pancreatitis 
[26] and pneumonitis [28]. However, these manifestations lie outside the scope of 
this thesis, as the focus is on alphaherpesvirus infections of the CNS. 
Primary infections with HSV-1 and VZV often occur during childhood, when 
the presentation is usually benign, while such infection later in life can be more 
severe. HSV-1 is often spread through contact with secretions such as saliva or 
breast milk, while VZV is airborne causing outbreaks in schools and day-care 
centres. HSV-2 spreads mainly via sexual contact or in rare cases from mother to 
child (congenital or post-natal infection) [29]. As the spread of HSV-2 is 
predominantly via sexual contact, the average age for primary HSV-2 infection is 
higher than for primary HSV-1 [30]. The seroprevalence of these viruses is high 
in the population, although HSV-2 has a lower seroprevalence (10-30%) than 
HSV-1 (50-80%) and VZV (80-100%) [29, 31-34]. 
As illustrated by the phylogenetic tree (Figure 1), HSV-1 and HSV-2 are more 
closely related to each other than to VZV [35]. In fact, VZV belongs to a different 
subgroup of alphaherpesviruses, namely the varicelloviruses, while HSV-1 and 
HSV-2 are part of the subfamily of simplexviruses. Previous work from our 
laboratory has shown that HSV-1 strains can be divided into three genetic groups, 
but frequent homologous recombination events during their evolution has resulted 
in mosaic patterns in all investigated clinical strains which complicates the 
genotyping [36].  
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Herpes simplex virus type 1 
HSV-1 virus is highly contagious. In 2012 it was estimated that around 3.6 
billion people under the age of 50 (67%) were infected worldwide; seroprevalence 
was estimated as 87% in Africa and 40-50% in the Americas [37, 38].  
As mentioned above, the most common manifestation of HSV-1 infection is 
oral herpes i.e. mucocutaneous lesions in the orolabial region. However, many 
infected persons are asymptomatic, and shed the virus unaware of that they are 
contagious [39]. HSV-1 is mainly transmitted through oral-to-oral contact, but can 
also be transmitted to the genital area, and in some Western countries, HSV-1 
Figure 1. The phylogenetic relationship within alphaherpesviruses. Simplexviruses and 
varicelloviruses are present in mammals, Mardiviruses and Iltoviruses are found in birds and 
Scutaviruses are prevalent in reptiles. Please note that not all existing alphaherpesviruses are 
represented in the figure. The three human viruses HSV-1, HSV-2 and VZV are highlighted in black. 
Cercopithecine herpesvirus 2 (CeHV-2), Papiine herpesvirus 2 (PaHV-2) and Herpes B virus 
(McHV-1) as well as Cercopithecine herpesvirus 9 (CeHV-9) all infect primates, but McHV-2 may 
also in rare instances infect humans resulting in severe brain infections. Pseudorabies virus (SuHV-
1) has been of special importance for neuroscientific research. The phylogenetic relatedness is based 
on aa sequence alignment for 6 genes (unique long region (UL) 15, UL19, UL27, UL28, UL29, UL30) 
performed by Davison [35]. 
BoHV = bovine herpes virus, EHV = equine herpes virus, GaHV = Gallid herpes virus, MeHV = 
Meleagrid herpesvirus, ChHV5 = Chelonid herpesvirus 5. 
HSV-1
HSV-2
CeHV-2
PaHV-2
McHV-1
BoHV-1
BoHV-5
SuHV-1
EHV-1
EHV-4
VZV
CeHV-9
Simplexvirus
Varicellovirus
GaHV-2
GaHV-3
MeHV-1
Mardivirus
GaHV-1
MeHV-1
ChHV-5
Iltovirus
Scutavirus
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infection has been reported to be almost equal or superior to HSV-2 as the primary 
cause of genital herpes in younger women [31, 38, 40-42]. In some circumstances, 
HSV-1 can be transmitted from mother to child during delivery (if the mother has 
a genital HSV-1 infection) [43, 44]. HSV-1 is also associated with the skin 
infections commonly known as herpetic whitlow (infection on fingers) and herpes 
gladiatorum or wrestler’s herpes (infection on the chest or face) [39]. Although 
HSV-1 is normally regarded as a “mild” virus, on rare occasions it can cause 
herpes keratitis [24] or severe CNS-infections such as herpes simplex encephalitis 
(HSE) that can be fatal. This manifestation will be described in detail later. 
HSV-1 can be transmitted through asymptomatic shedding from the mucosal 
surfaces, saliva and breast milk, but transmission from active lesions is more 
common, and constitutes a greater risk. As for all herpesviruses, latent infection 
is established after active infection with HSV-1, and the trigeminal nerve is the 
preferred site of latency. HSV-1 infection can be asymptomatic, but it can also be 
recurrent. On reactivation, HSV-1 can be transported anterogradely via the 
neuron’s axon to the skin where virus is shed and new lesions may reappear in the 
affected area. These recurrences can be triggered by various stimuli, including UV 
radiation, radiotherapy, trauma, upper respiratory tract infection, stress and 
menstruation [39]. Reactivation will be discussed in detail in a later section. 
In adults, the primary infection can be more painful and more extensive than 
recurrent episodes [45], while primary infection in childhood usually is mild or 
goes unnoticed [46]. However, primary gingivostomatitis, where extensive and 
painful blistering appears on the lips and on the tongue and mucosal surfaces 
inside the mouth, can occur also in children [46, 47].  
In 2012, 140 million of the world’s population aged 15-49 years was estimated 
to have a genital HSV-1 infection [37], but the prevalence varied between different 
regions, where Europe, the Americas and the Western Pacific had the highest 
prevalence. This is probably related to the fact that HSV-1 infection is acquired 
well into the adolescent years in Western countries, while in Africa HSV-1 
infections mostly are acquired during childhood. In the Western world, better 
hygiene and awareness of that herpetic lesions can spread virus might have 
reduced the transmission of HSV-1 in childhood, when the infection is milder, and 
increased the spread of HSV-1 upon sexual debut [48].  
Herpes simplex virus type 2 
HSV-2 is the human alphaherpesvirus with the lowest seroprevalence 
worldwide, with 417 million people (11%) estimated to be infected in 2012 [29]. 
The infection is rare in children, and most primary infections are found among 
adolescents and young adults. As for HSV-1, the seroprevalence is not evenly 
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distributed between the continents. HSV-2 infection shows the highest prevalence 
in Africa (31.5%) followed by the Americas (14.4%) [29].  
Almost exclusively transmitted sexually [49], and mainly associated with 
genital herpes [31], HSV-2 is more prevalent in women [32], since sexual 
transmission of HSV-2 from man to woman may be more efficient than from 
woman to man. Like HSV-1, HSV-2 infection is often asymptomatic and can be 
transmitted through shedding from areas that lack signs of infection [50].  
The preferred site of latency for HSV-2 is the sacral ganglia, which innervate 
the genital area. While mainly being transmitted sexually, HSV-2 can also be 
transferred vertically in utero as a congenital infection, or during delivery from 
infected mother to child. Such transmission can cause a neonatal herpes infection, 
which can be fatal. Besides the severe neonatal herpes infection, HSV-2 can also 
cause meningitis in adults. The CNS infections caused by alphaherpesviruses will 
be described in more detail later in this thesis. 
Having an HSV-2 infection increases the risk for acquiring HIV (up to three-
fold increase [51]), and individuals co-infected with HIV and HSV-2 have 
increased risk for spreading HIV to others (reviewed in [52]). These patients, as 
is the case for other immunocompromised individuals, often have more frequent 
severe and painful recurrences than do immunocompetent individuals. 
Varicella Zoster virus 
VZV, which causes chickenpox (varicella) as primary infection and shingles 
(zoster) after reactivation, is one of the most prevalent viral infections in humans 
[34]. While primary HSV infection may be asymptomatic, primary VZV infection 
is usually symptomatic in form of varicella, which in the Western world is a 
common childhood infection. Unlike HSV, the skin lesions are generally 
distributed over the upper part of the body and may, in addition to epidermal 
location, go deeper and engage dermis. Like other alphaherpesviruses, VZV can 
establish latency in sensory ganglia (along the entire neuroaxis) from where the 
virus reactivates to cause herpes zoster. In zoster, ulcers and pain usually appear 
along the dermatome of a sensory nerve of the specific ganglion from which the 
virus has reactivated, while virus remains latent in other ganglia along the 
neuroaxis. VZV spread is truly airborne, and both varicella and zoster patients can 
transmit infection to a seronegative person, although zoster patients are regarded 
as less contagious than varicella patients. However, it is believed that varicella 
outbreaks can be triggered by transmission from zoster patients, for example a 
grandparent meeting with a seronegative grandchild. Unlike HSV, VZV primary 
infection usually results in viraemia, and while HSV is thought to access neuronal 
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ganglia only from the axons in the skin, VZV may also access neurons via immune 
cells during viraemia (reviewed in [53]).  
Like HSV, VZV can infect the CNS following both primary infection and 
reactivation, and such infections can occur without any signs of skin 
manifestations. In Sweden, VZV is reported to be the second or third most 
common cause of viral CNS infection [54] and this virus is related to many 
different clinical CNS manifestations, including encephalitis, myelitis and 
cerebellitis, which are described later in the thesis. 
 
2.2 Structure of a herpes virion 
 
All herpesviruses share a common structure (Figure 2). In the centre, a DNA 
core with linear double-stranded DNA is located, which is surrounded by an 
icosahedral capsid. Outside of this, a space called the tegument is located, which 
contains proteins and enzymes that facilitate initiation of replication. The 
tegument in turn is enclosed by an envelope where several different glycoproteins 
are inserted.  
Figure 2. Structure of a herpes virion. Double-stranded, linear DNA is located inside the icosahedral 
nucleocapsid, which is surrounded by tegument proteins. This capsid is in turn surrounded by the viral 
envelope on which surface viral glycoproteins are exposed. Note that in de-enveloped virions, the 
genome is circularized [39].  
Nucleocapsid
(icosahedral)
Viral genome
(double-stranded DNA)
Tegument
Envelope
Glycoproteins
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Viral genome 
Alphaherpesvirus genomes commonly share four structural components: the 
unique long (UL) and the unique short (US) regions, the terminal repeat (TR) 
regions, flanking the ends of the genomes, and the inverted repeat (IR) regions, 
linking the unique regions together (Figure 3). While the UL regions encode 
single-copy genes, the IR regions may code for diploid genes, as well as sequences 
required for viral DNA cleavage and package. 
Interestingly, alphaherpesviruses display isoforms of their genomes. HSV have 
four isomeric forms, present in equal proportions, while VZV show two 
predominant isoforms. The isomeric forms of the genome have emerged from 
inversion of the unique sequences relative to each other. For HSV, both the UL 
and the US can be inverted. Technically, VZV do have four isoforms, but the 
inversion of UL only occurs in around 5% of the total genomes, due to the 
existence of much shorter TR and IR adjacent to the UL region [55]. Thus, the two 
dominant VZV isoforms are due to inversions in US.  
As can be seen in Figure 3, the genomes of HSV-1 and HSV-2 are considerably 
larger than the VZV genome. Furthermore, the TR and IR adjacent to the UL 
region are much longer for HSV than for VZV. In addition, the G+C content 
(Figure 3) is high for HS but low for VZV, which also underscores the large 
differences between the viruses and supports the genetic diversity demonstrated 
in the phylogenetic tree (Figure 1) [55]. 
The genome of HSV-2 is more homologous to HSV-1 than to VZV, but there 
are nevertheless large differences between the two HSV genomes as well. The 
overall nucleotide identity between HSV-1 and HSV-2 is approximately 50% [56], 
and the differences in the genomes, and the resulting differences in structure and 
functions of glycoproteins, could explain the type-specific preferences for sites of 
latency and lytic infection. 
Figure 3. Human alphaherpesvirus genomes. UL= unique long region, US= unique short region, IRL= 
internal repeat long region, TRL= terminal repeat long region, IRS= internal repeat short region, TRS= 
terminal repeat short region. G+C represents the content of guanine and cytosine in the genome, 
indicative of the number of three-hydrogen bonds in the DNA chain. High G+C percentage indicates 
that the HSV chromosome is more stable than VZV DNA with its low G+C percentage. 
TRL IRL IRS TRS
UL US
HSV-1
HSV-2
TRL IRL IRS TRS
UL
US
VZV
IRS TRS
US
IRLTRL
UL
125 kbp
155 kbp
152 kbp 68.3% G+C
70% G+C
46% G+C
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HSV glycoproteins and their role in cell entry 
Envelope glycoproteins are decisive in early virus-cell interactions, in 
attachment to and fusion with the host cell and in the immune escape of the virus. 
Alphaherpesviruses encode a multitude of their own glycoproteins, which are 
glycosylated by the host cell machinery. Glycans attached to the viral 
glycoproteins can either be N-linked (attached to asparagine residues) or O-linked 
(attached to serine, threonine or tyrosine residues). While HSV-1 and HSV-2 
encode for at least 12 glycoproteins [57-59], the VZV genome is smaller, in 
particular the US region, and encodes fewer glycoproteins [28]. The VZV cell 
entry is less well studied than that of HSV, and the entry receptors are partly 
different, but as the major focus of this thesis is HSV-1, only the HSV 
glycoproteins and their cell entry procedures will be described here. 
 Five glycoproteins participate in HSV cell entry: glycoprotein B (gB), gC, 
glycoprotein D (gD) and the complex of glycoproteins H and L (gH/gL). For HSV-
1 and HSV-2, gB, gD and gH/gL are essential glycoproteins in cell culture while 
gC is dispensable. The functions of all known glycoproteins of HSV are described 
in Table 1. Glycoproteins involved in cell entry are also described further below.  
 During HSV entry, the virus can bind at least four different receptors with its 
glycoproteins, as is illustrated in Figure 4. Replication of herpesviruses is initiated 
when the viral glycoproteins interact with the surface receptors of the host cells. 
Figure 4. Viral entry into cells assisted by glycoproteins.  
(1) An HSV-1 virion approaches the cell surface. 
(2) Viral glycoproteins interact with host cell surface receptors. Glycoprotein C (gC) and partly gB 
binds to HS, which brings the virion closer to the cell membrane, where gD can bind HVEM, Nectin-
1 or -2, or a modified form of HS and gB can bind PILRα as a co-receptor. 
(3) Virion attaches to host cell surface, where binding to receptors induce a conformational change 
in gD, which activates gB and gH/gL.  
(4) Virion envelope fuses with the cell plasma membrane, assisted by gB and the complex of gH/gL. 
This leads to release of the capsid into the cytoplasm along with the tegument content.  
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The primary interaction is between the viral attachment protein gC and heparan 
sulphate (HS) [60, 61] or chondroitin sulphate (CS) when HS is absent [62, 63]. 
Although gC is known to be non-essential for cell-entry, HSV-1 virions deficient 
in gC (gC-1 negative virions) are rarely found in nature and have been shown to 
display reduced infectivity [60]. HSV-1 gB (gB-1) can also interact with HS 
although, in gC-1 wild-type virus, this interaction is less important than gC-1 
binding [64]. For HSV-2 virions, gC may not be as important during the initial 
attachment phase as for HSV-1, and gB-2 has instead been suggested to be of 
greater importance for HSV-2 binding to HS [65, 66]. Special focus on gC will be 
given in a separate paragraph. 
After initial attachment, gD can bind to any of the natural receptors: nectins, 
herpesvirus entry mediator (HVEM) or 3-O-sulfated HS (Figure 4). Furthermore, 
the paired immunoglobulin-like receptor α (PILRα) can be used as a co-receptor 
for cell entry through binding via gB [67]. The next paragraph will discuss the 
different entry receptors in detail.  
 After binding to the host cell, a conformational change in gD is induced, which 
activates gB and gH/gL-mediated fusion between the virion envelope and the 
plasma membrane (Figure 4). This in turn leads to a release of the capsid into the 
cytoplasm, while the content of the tegument (enzymes and transcription factors 
for initiation of viral transcription) also finds its way into the cell. Docking of the 
capsid with the nuclear membrane leads to release of the genome into the nucleus 
where it circularizes, and can be transcribed for replication. The transcription 
process is performed by a cellular RNA-polymerase, but the procedure is 
controlled both by virus-encoded and cellular nuclear factors. Here, the biological 
decision of HSV lytic replication or latency is determined and the expression of 
responsible genes is triggered. Since latency will be described in detail in the 
chapter on viral infections in the CNS, only the fate of lytic infection will be 
described in this section.  
 In a lytic infection, the infected cell produces infectious virions. HSV and VZV 
encode for their own DNA polymerases and other relevant enzymes, such as the 
viral thymidine kinase, which promote viral DNA replication. Newly synthesized 
viral DNA enters the empty procapsids within the nucleus, and the virus exits 
through the nuclear membrane. After this, the virus obtains its envelope with 
newly produced glycoproteins during its passage through the Golgi and ER 
networks. Finally, the virus exits the cells by exocytosis or lysis of the cell 
membrane, to spread to new cells in the same host, or to a different host. In lytic 
infection, the virus regulates the metabolism of the host cell as well as the protein 
synthesis, the cell cycle and intrinsic and innate cell responses [22].  
 Histopathologically, lytic infection is associated with swelling of cells and 
degeneration of the cell nuclei and loss of intact plasma membranes, leading to 
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formation of multinuclear, giant cells and cell lysis. Lytic infection leads to 
recruitment of an intensive inflammatory response, though this activity is 
significantly lower during recurrent disease. 
 
Table 1. HSV glycoproteins  
Glycoprotein HSV-
gene 
Gene function 
gB UL27 Fusion protein that, together with gH and gL [68, 69] is essential for infectivity of virions and fusion between cells. gB is required for cell 
entry but also participates in the initial interactions with the cell 
surface HS [60] together with gC. gB can bind to PILRα [67], and is 
essential for infection in cell culture. 
gC UL44 Mediates the attachment of virions to cells through binding to HS [60] or CS [63]. gC-1 can also bind complement component 3b (C3b) and 
block binding of complement components C5 and properdin to C3b, a 
function which gC-2 lacks on whole virions [70].  
gD US6 Defines viral tropisms through interactions with the entry receptors HVEM [71], 3-O sulphated HS [72] nectin-1 [73] and nectin-2 
(particularly relevant for wild-type HSV-2, although specific 
mutations in HSV-1 gD (gD-1) can also induce binding via nectin-2 
[10]). gD initiates a conformational change leading to exposure of 
domains involved in fusion, thereby allowing gB, gH and gL to 
complete the fusion between the virion envelope and the plasma 
membrane [68]. gD is essential for infection in cell culture. 
gE US8 Forms a heterodimer with gI, but gE is the major constituent in the viral Fc receptor and is involved in antihost defences [74, 75]. gE is 
essential for HSV anterograde spread along with gI [74, 76, 77], and 
important for axonal targeting and retrograde transport [74, 78].  
gG US4 Precise function unknown, but HSV-2 gG (gG-2), which is considerably larger than gG-1, has been show to bind chemokines and 
may be of importance for immune evasion [79]. gG-1 may enhance 
apical infection of polarized cells [80]. 
gH UL22 A fusion protein that is essential for the infectivity of virions and fusion between cells. gH interacts in a complex with gL and is essential 
for infection in cell culture [81]. gH can induce neutralizing antibodies 
[82]. 
gI US7 Forms a heterodimer with gE, where the complex forms a viral Fc receptor for immunoglobulin G (IgG) [75]. In polarized cells, such as 
epithelial cells, the complex can assist in basolateral spread of progeny 
virus. gI is essential for HSV anterograde spread along with gE and 
probably also with US9 [77]. 
gJ US5 Blocks apoptosis [83]. 
gK UL53 Inhibits fusion between infected cells and adjacent cells. Appears to 
be of importance in the interaction between gB and PILRα [84]. 
Reported to promote viral egress [85]. 
gL UL1 Appears to regulate the fusogenic activity of gH and is thereby essential for cell fusion [86]. gL is not anchored to the plasma 
membrane [87] but is found in complex with gH and is essential for 
infection in cell culture.  
gM UL10 Might be required for package of gN into virions, with which it interacts [88, 89]. gM is suggested to be required for efficient 
membrane fusion during viral entry and spread [90]. 
gN UL49.5 Reportedly blocks endogenous antigen presentation. gN interacts with gM [89]. 
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HSV entry receptors 
 As mentioned above, there are three known classes of entry receptors for gD, 
one receptor for gB and two attachment receptors for gC (and partially gB). 
 HS, highly sulphated carbohydrate polymers covalently linked to proteins (so 
called proteoglycans, see below) or to lipids inserted into the cell membrane, 
usually function as attachment molecules for HSV via gC and gB, but gD can also 
utilize the modified form of 3-O-sulfated HS as its specific receptor. Members of 
the 3-O-sulfotransferase enzyme family modify HS, and can be found in the brain 
but also elsewhere in the body [91, 92]. The presence of this enzyme in the brain 
suggests the importance of this specific HS receptor for HSV-1 infection in the 
CNS [72], though the exact entry mechanisms are still unclear. HS and CS, as 
mentioned above, are constituents of proteoglycans with a cell-associated core 
protein (carbohydrate backbone) and GAG chains bound to serine residues on the 
backbone [93]. The GAG chains consist of numerous linear repeats of 
disaccharide motifs, synthesized via a dynamic process in three phases, which can 
include different enzymes depending on cell type and stage of cell differentiation 
[94]. Depending on which sugar residues that are combined in the initial 
disaccharide motif of the GAG chain, different families of enzymes are activated, 
resulting in synthesis of either HS or CS chains [93]. Virus can bind to sulphated 
oligosaccharide motifs on GAGs, which are negatively charged due to the sulphate 
groups. Therefore, electrostatic forces are of importance in the attachment 
interactions between the viral glycoproteins and the proteoglycans [93]. 
HVEM is a cell-surface receptor belonging to the tumour necrosis factor 
receptor (TNFR) superfamily; it is expressed by T lymphocytes as well as by 
epithelial and neuronal cells [71, 95-99]. The natural function of HVEM appears 
to be regulation of the mucosal microbiota and the epithelial barrier [100]. 
Upregulation of HVEM expression via the latency-associated transcript (LAT) has 
recently been suggested to enhance reactivation of HSV from latency [101]. 
 The intracellular adhesion molecules in form of nectins are found on epithelial 
and neuronal cells [96-99, 102-105]. Nectins are members of the immunoglobulin 
(Ig) superfamily and complexes can be formed between nectins on adjacent cells 
[73, 106]. HSV-1 binds mainly to nectin-1 while wild-type HSV-2 and HSV-1 
strains with specific gD-1 mutations also can bind to nectin-2 [10, 101, 107]. 
 Finally, PILRα can trigger viral fusion in certain cell types upon binding to gB 
[67]. PILRα is found on monocytes, macrophages and dendritic cells and normally 
delivers inhibitory signals to the host cell. Binding of gB to PILRα may therefore 
also provide the virus with an immune escape route (reviewed in [108]) but the 
significance of this receptor needs further investigation.  
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Glycoprotein C of HSV-1 
All three alphaherpesviruses carry gC (the UL44 gene) on their envelope, but 
while gC of HSV-1 and HSV-2 (gC-1 and gC-2, respectively) are highly 
conserved (65% similarity, where most divergence is seen in the N-terminal 
region), VZV gC only display 30% genetic similarity with gC-1. Nevertheless, 
VZV gC might also utilize HS as an initial receptor [109]. gC is a type-1 
membrane glycoprotein, which is highly glycosylated by both N-linked 
(attachment via nitrogen atoms on amino acid (aa) residues) and O-linked 
(attachment via oxygen atoms on aa residues) glycans.  
As mentioned in the previous section, HSV gC can mediate the binding of HSV 
to cell surface GAGs such as HS and CS. gC-negative virus can still bind to GAGs 
on the cell surface via gB [60], though it has been reported that gC-1 deficient 
virus has a reduced infectivity compared with wild-type virus. Furthermore, 
although gC-1 may be non-essential in cell culture experiments, the gC-1 
glycoprotein appears to have an important function for HSV-1 infection in 
humans, where purified gC-1 alone has been demonstrated to mediate binding to 
HS in the absence of other viral glycoproteins [112]. The interaction between HS 
and purified gC-2 has been demonstrated to be superior in binding strength to that 
of HS and gC-1 [65, 66]. This feature is most likely related to the divergence 
between gC-1 and gC-2 in the N-terminal region. Here, a mucin-like region, rich 
in O-linked glycans can be found on gC-1 (Figure 5, 6); this domain is absent in 
the gC-2 genome. Instead for HSV-2, a mucin-like region similar to that of gC-1 
is found on gG-2. The mucin-like region of gC-1 has been found to be essential 
for the interaction with GAGs, where it functions as a negative binding modulator 
for gC-1 as compared with gC-2; and this property could regulate viral tropism 
[113]. In the presence of other glycoproteins such as gG-2, the interactions 
Figure 5. Map of gC-1. Mucin-like region glycosylation in enlargement, adapted from [110]. 
Hexagonal stick corresponds to location of N-linked glycans. Rhomb-shaped, green stick 
corresponds to O-linked glycan pattern as identified in [111] Monoclonal antibody B1C1 binds to 
the loop structure in antigenic site II. Red line and aa marked (129-155 + 247) represent the GAG-
binding site. TMR = transmembrane region, GalNAc = N-acetylgalactosamine, Gal = galactose, SA 
= sialic acid, Ser = serine, Thr = threonine. 
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between HS and HSV-2 are reduced, most likely due to shielding of the gC-2 
binding site through the mucin-like region of gG-2.  
Two antigenic sites, representative of the epitopes of gC-1, have been mapped 
[114]. Antigenic site II was localised to aa 129-247, adjacent to the mucin-like 
region, while antigenic site I is found at aa 307-373 (Figure 5). The actual GAG-
binding site of gC-1 is located carboxyterminally of the mucin-like region within 
the protein (Figure 5), where the basic and hydrophobic residues at the loop 
structure in the antigenic site II participate in the GAG-binding domain [115]. The 
monoclonal antibody (mab) B1C1, which was used to define antigenic site II 
[116], has been demonstrated to block the interaction between gC-1 and cell 
surface HS efficiently in vitro as well as in vivo, thereby neutralizing viral 
infectivity [117].  
The mucin-like region (Figure 5) is a region rich in threonine (Thr) and serine 
(Ser) residues, which are densely decorated with O-glycans [118]. The O-
glycosylation sites of gC have recently been identified [111], where the 
localisation of nine sites were determined within one-half of the mucin-like 
region. Norden et al. [110] described the stepwise addition of the glycans to the 
mucin-like region, where N-Acetylgalactosamine (GalNAc) transferases initiate 
the dynamic O-linked glycosylation with addition of GalNAcs to only a few 
specific Ser and Thr residues. This initiation is then followed by GalNAc 
modification in an ordered “seed-and-spread” pattern, before other 
monosaccharides can extend the residues as seen in Figure 5.  
The function of the mucin-like region, also containing basic aa:s, has been 
attributed to electrostatic and modifying interactions with the GAGs on cell 
surfaces, and to cell-to-cell spread of the virus [113, 119] (Figure 6). Furthermore, 
the region appears to participate in induction of selectin ligands via carbohydrate 
Figure 6. The electrostatic interactions between negatively charged GAGs on the cell membrane and 
the positively charged binding site of glycoprotein C on HSV-1 (gC-1) is modulated by the mucin-
like region. HS= heparan sulphate. CS = chondroitin sulphate.  
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bindings, which could possibly influence viremic spread of HSV-1 [120, 121]. In 
addition, O-linked glycosylation of a mucin-like domain on a gammaherpesvirus 
has been shown to shield vulnerable epitopes on viral glycoproteins from 
neutralizing antibodies [122]. This could also be true for the mucin domain of gC-
1. In addition, a recent study on HSV-2 has demonstrated that viral O-linked 
glycans, for example present on gG-2, were recognized by chemokines at 
epithelial surfaces early in infection, before the actions of interferons [123]. 
In addition to its GAG-binding function, gC-1 has in cell culture experiments 
been shown to function as a receptor for complement component 3b (C3b), a part 
of the innate immune response. By introduction of four non-relevant aa residues 
in a walking manner, the interaction with C3b was localised to four gC-1 regions: 
aa 124-137, aa 279-292, aa 339-366 and aa 223-246 [124]. Interestingly, the first 
C3b binding region is located within the antigenic site II, and, like GAG binding, 
this interaction can be blocked efficiently by the mab B1C1 (Figure 7) [125]. 
Deletion of the mucin-like region (aa 33-123) does not reduce binding of C3b, but 
appears to prevent binding of other complement components to the C3b complex 
[126] and also to reduce the affinity for HS [127]. Interestingly, the mucin-like 
region has not been shown to not participate in the binding of C3b, but instead it 
interferes with another complement factor, properdin [126].  
The binding of C3b has also been located on three sites of purified gC-2 [70], 
but not on the surface of HSV-2 virions [124, 128, 129]; this suggests that the 
manner in which the glycoprotein is presented on the viral envelope might 
influence the binding of C3b. Nevertheless, gC-2 can also block the complement-
mediated neutralization [130]. Further implications of the C3b binding will be 
discussed below in the section on the complement system. 
Interestingly, gC-1-negative strains are very rarely isolated from patients, 
further implicating the importance of gC-1 for viral replication and infectivity in 
vivo. In addition, it has been suggested that the structural variations of HS could 
contribute to the wide cell and tissue tropism presented by HSV-1 [131], which 
would mean that gC-1, and the mucin-like region, is highly involved in viral 
tropism.  
Figure 7. The four regions of HSV-1 gC-1 binding to C3b as demonstrated in [70]. Monoclonal 
antibody B1C1 bind to C3b-binding region I. C5/P blocking domain corresponds to the mucin-like 
region. P = properdin. TMR = transmembrane region.  
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2.3. Viral infections in the CNS 
The CNS is a part of the body normally relatively well protected from external 
microbial invasion by several defence mechanisms including the blood brain 
barrier (BBB). Therefore, CNS infections are rare in comparison with, for 
example, infections involving the respiratory tract and the gastrointestinal system, 
but when opportunities to enter the CNS arise for a pathogen, the spread can occur 
through three different pathways: through neuronal or haematogenous spread, or 
locally via eyes, nose or sinuses.  
The CNS has its own defence against infections, including microglia and 
astrocytes that release, among other substances, chemokines and cytokines to 
recruit immune cells from the systemic circulation. Despite this defence, 
pathogens in the form of bacteria, protozoa, viruses and fungi, which succeed in 
passing across the BBB, can establish severe infections with risk for lethal 
outcome. Furthermore, many CNS infections can result in residual symptoms or 
sequelae that can permanently affect the everyday life of the patient. Detection of 
microbial agents causing the infection can be done through analysis of 
cerebrospinal fluid (CSF), serum/plasma and vesicular fluid, or, in some instances, 
urine, faeces and/or nasopharyngeal secretions. Earlier, brain biopsies subjected 
to virus culture were utilized for diagnosis, but with the introduction of sensitive 
and specific polymerase chain reaction (PCR) methods, far more cases than before 
are linked to specific viral pathogens [132].  
Viral CNS infections 
CNS infections can be caused by a variety of viral agents and are most often 
acute but can, on some occasions, be chronic. The aetiology of these infections, 
which can be sporadic or endemic, can vary in different geographical regions. 
Zoonotic viruses common in warmer regions such as Zika virus [133], Japanese 
B encephalitis virus [134], Dengue virus [135], Yellow fever virus [135], West 
Nile virus [136] and Rabies virus [137] are regularly detected in a global setting. 
Viruses more common in Northern European settings, such as enteroviruses [138], 
herpesviruses [132], tick-borne encephalitis (TBE) virus [139], adenoviruses and, 
on rare occasions, influenza viruses [140], have all been associated with viral CNS 
infections. Several childhood infections such as rubella [141], morbilli [142], 
parotitis [141] and polio [137] may also cause CNS disease, but these infections 
have been successfully defeated due to general vaccination programs. The clinical 
picture itself is rarely enough to determine which virus has caused the CNS 
infection in question [132]. Other symptoms of infection, such as fever, 
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respiratory difficulties and gastrointestinal manifestations may occur 
concomitantly with viral CNS infections, but can be absent and therefore 
laboratory diagnosis of such viral infections is important. Included among routine 
diagnostic methods is detection of viral nucleic acids by PCR, followed by gene 
sequencing for identification of viral strains and, to a lesser degree, isolation of 
virus in cell culture and antigen detection. As an indirect method, demonstration 
of IgM and IgG antibodies in the CSF and serum is useful [132]. 
Determination of the viral agent causing the infection is successful in around 
50-60% of all patients [143-145], and in many of these cases, the diagnosis leads 
to initiation of antiviral treatment to target the responsible virus.  
Viral CNS infections are manifested in several clinical entities, including 
encephalitis, meningitis and myelitis. Encephalitis is often severe, while viral 
meningitis normally is a milder condition (especially as compared with bacterial 
meningitis) and can in most cases resolve after 7-10 days. Although the CSF 
laboratory findings are different in viral meningitis as compared with those in 
bacterial meningitis, clinical symptoms including headache and nuchal rigidity are 
often similar. Viral encephalitis on the other hand is often associated with focal 
symptoms and neurological sequelae, which may also occur in bacterial 
meningitis [146-149]. Apart from the distinct conditions of encephalitis and 
meningitis, meningoencephalitis, as a condition involving both the brain and the 
meninges, is commonly reported for many neurotropic viruses [139, 150-155].  
The national surveillance of polio and other CNS viruses requires that all viral 
meningoencephalitis cases are to be reported to the Public Health Agency of 
Sweden (Folkhälsomyndigheten, FoHM). Each year statistical reports are 
presented on their website, available also for the general public. However, not all 
cases of viral CNS infections are reported to the FoHM, apart from those caused 
by polio, other enteroviruses and TBE. Moreover, the definition of 
meningoencephalitis held by the FoHM [156] does not appear to correspond to 
the previously described definition, possibly resulting in inclusion of the less 
severe cases of meningitis as well. Between 2010 and 2015, the approximate 
average number of reported cases of meningoencephalitis per year was 880, a 
number that includes both domestic and imported cases (Figure 8).  
Enteroviruses, which constitute 30-40% of all reported cases of viral 
meningoencephalitis (Figure 8), are the most common cause of viral meningitis in 
Sweden. Enteroviruses display a seasonal appearance, being more common during 
the end of summer and the beginning of autumn, as compared with the incidence 
during the rest of the year [54]. The virulence of the circulating enterovirus strains 
determines the number of CNS infections caused by these viruses and explains the 
variable incidence between years. Second to enteroviruses, the most common 
cause of viral meningoencephalitis in Sweden is TBE, being the causative agent 
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in 20-30% of the total number of cases (Figure 8). In fact, in 2015, CNS infections 
due to TBE virus even marginally exceeded those caused by enteroviruses. 
In the Western world, the most common cause of sporadic, focal viral 
encephalitis is HSV-1, while HSV-2 induces meningitis that may be recurrent. In 
contrast, VZV shows diverse clinical manifestations within the CNS including 
meningoencephalitis, encephalitis, cerebellitis, meningitis, myelitis and focal 
neuropathies including post-herpetic neuralgia (PHN). VZV is reportedly the most 
commonly detected alphaherpesvirus in CSF samples from patients with CNS 
symptoms in western parts of Sweden [157]. Furthermore, other herpesviruses, 
including HHV-6, EBV and CMV, are also detected in clinical studies of viral 
Figure 8. Reported cases of viral CNS infections in Sweden 2010-2015, adapted from data collected 
by the Public Health Agency of Sweden (FoHM) [54]. Note that only about 50% of all 
meningoencephalitis cases in Sweden are reported to the FoHM. * = HSV type undefined. The group 
“Other herpesviruses” includes HHV-6, EBV and CMV. The group “Other viruses” includes 
adenovirus, West Nile virus, Japanese encephalitis virus, JC virus, Toscana virus, mumps virus and 
parechovirus. 
TBE
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meningoencephalitis; in together they represent a substantial proportion of viral 
CNS infections (Figure 8).  
Up until now, the majority of meningoencephalitis cases in Sweden have been 
contracted domestically. However, increased travel and immigration from 
countries where vaccination coverage is insufficient and also affected by the 
global warming leading to an introduction of arthropod-borne virus (arbovirus) 
infections to geographic locations previously not stricken (reviewed in [21]), 
might change the aetiology of viral meningoencephalitis in the future. Indeed, 
during the last six years, a few meningoencephalitis cases caused by “exotic” 
viruses, including West Nile virus and Japanese encephalitis virus, have been 
reported in Sweden [54]. However, the Swedish cases are substantially fewer than 
what is seen in other Western countries, such as the US and the southern parts of 
Europe, where these infections have become domestic. This has been described, 
among others, for West Nile virus [158], Dengue virus [159] and most recently 
for Zika virus (in Florida) [133]. 
Cell culture and animal models for studying alphaherpesvirus 
infections in the CNS 
 Although human alphaherpesviruses show a wide tropism and therefore can 
infect many cell types, CNS infections in cell culture models can only be studied 
in cells derived from that lineage. To date, few such cell culture systems adequate 
for studies of the pathogenesis of these viruses have been described. Cultured 
oligodendrocytes, astrocytes and whole trigeminal ganglia have all been infected 
in vitro with alphaherpesviruses, with demonstrable cytopathogenic effect [160-
163]. One promising method recently introduced is the reprogramming of a cell 
culture towards human induced pluripotent stem cells (iPSCs) [164]. Subsequent 
differentiation into neuronal cells results in a cell culture driven towards the cell 
type of interest [165-168]. A few studies with alphaherpesvirus infection of iPSCs 
have been presented to date [169-171]. iPSCs offer a great possibility for 
maturation into a large variety of cell types, but differentiation can only be driven 
towards cells within a specific embryonic layer (Figure 9). In line with this, 
astrocytes, neurons and oligodendrocytes are all of interest and can be produced 
from the same iPSCs as they all originate from the ectoderm [166, 169]. However, 
microglial cells, which originate from mesoderm, will not appear in the same stem 
cell-derived culture as other neuronal cells. 
 Several animal models have been used to study alphaherpesvirus CNS 
infections in vivo, including those of rats, mice, guinea pigs and rabbits [28, 39]. 
Both the olfactory bulb and the trigeminal ganglion can be involved in 
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establishment of persistent infections [172], but the routes these viruses exploit 
for further spread within the CNS have been less extensively examined [173, 174].  
One of the most challenging questions of infection with alphaherpesvirus in 
animal CNS models is the understanding of how the virus can infect the CNS 
without inflicting damage to the surrounding structures. Many animal studies have 
used intracranial (i.c.) inoculation to ensure that the virus is distributed to the right 
location, though this is most likely an unnatural route of infection [175-177]. For 
VZV, animal models outside primates have been difficult to find.  
 Interestingly, studies have demonstrated that HSV-1 and HSV-2 behave 
differently in CNS after infection of rats, as regards neurovirulence and 
neuropathology; this demonstrates that rats are a useful model for discrimination 
between the CNS manifestations of these two viruses [175]. 
Latency and reactivation – neuronal transport and the fate of the 
infected neuron 
 After lytic infection with alphaherpesvirus in cell culture, the infected cell is 
usually destroyed. However, in sensory neurons, the alphaherpes virion can also 
Figure 9. Differentiation routes for iPSCs reprogrammed from the original cells. Differentiation 
route for neuronal cells is highlighted in bold. Please note that microglial cells originates from 
mesoderm and can therefore not be obtained in a cell culture differentiated into ectoderm. 
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enter a latent state after infection, in which the genome is found in its circularized 
state in the nucleus of the neuron [178]. During latency, the expression of viral 
lytical genes is restricted, while a subset of genes, including LAT, is expressed 
[179, 180]. Here, the viral genome is maintained and protected from the 
destructive mechanisms of cellular and host defences.  
 The virus can reactivate from the latent state in the sensory ganglia to replicate, 
and to be transported peripherally to induce a lytic state in the innervated skin 
region during which new infectious virions are produced. The precise mechanisms 
responsible for the virus reactivation from a latent state are unknown. 
Interestingly, the phosphorylating activity of viral thymidine kinase (TK; targeted 
by antiviral treatment) is thought to be of importance in mature neurons, as these 
are post-mitotic and lack expression of the cellular TK [39]. Triphosphorylated 
nucleoside precursors are required for DNA synthesis, and without the activity of 
the viral TK, viral replication would probably not occur in neurons. 
 The fate of the neuron after reactivation of an alphaherpesvirus has been 
debated, but most probably, the neurons survive, at least in HSV infection. This 
has been based on two observations; patients with frequently recurrent lesions at 
the same site do not suffer from local anaesthesia; and virus is shed from 
microscopic lesions between clinical manifestations in women with recurrent 
genital herpes [39].  
 The immune response has been suggested to play a role in preserving the latent 
infection, where CD8+ T-cells and interferon γ (IFN-γ) can block viral gene 
expression and replication [181, 182]. Although there have been many studies 
presented on this subject, the role of especially the innate immune mechanisms of 
the host needs to be investigated further. 
 Already during the 1920s, Goodpasture and Teague observed that HSV could 
spread via axonal transport, and demonstrated that retrograde neuronal transport 
from the periphery may introduce the infection into the CNS [183, 184]. This 
observation was later confirmed by other studies in animal models and two-
chamber cell culture systems of sensory neurons [185-191], where infection of 
virus in the periphery mostly leads to retrograde transport along the axons to the 
nerve cell body (Figure 10). In reactivation of virus from latency, axonal transport 
occurs in an anterograde fashion (Figure 10), to the skin and this might explain 
how reactivated virus can enter the brain. Interestingly though, while latent virus 
usually is found in the cell body of sensory neurons, HSV DNA findings have 
been reported from the brain during autopsy of patients without any symptoms of 
HSV CNS infections [192, 193]. 
Retrograde and anterograde HSV transport can be used for neuronal tracing to 
determine the distribution of axons and dendrites, where retrograde spread of 
infection is defined as spread of virus from a postsynaptic neuron to an uninfected 
 
24  C HAR LOTT A ER IKSSON  
presynaptic neuron and anterograde spread originates from a presynaptic neuron 
and proceeds to an uninfected postsynaptic neuron (reviewed in [194]).  
 Furthermore, in an experiment where mice were pre-treated with capsaicin (the 
substance causing burning sensation in chili pepper) before infection with HSV-
1, it was demonstrated that the mortality rate was reduced in both acute and latent 
infections [195]. This outcome might be explained by the capsaicin treatment. 
Such treatment could cause degeneration of unmyelinated sensory neurons in the 
trigeminal ganglia, resulting in decreased availability of surrounding glial cells for 
infection, in turn a confirmation of neuronal transport for HSV-1. Interestingly, a 
more recent study has also revealed that in vitro, capsaicin can reactivate a latent 
HSV-1 infection in a neuronal cell culture [196]. 
Figure 10. Top: Establishment of alphaherpesvirus latency in sensory neurons of ganglia. The 
alphaherpesviruses enters the neuron from the site of a lytic infection in another cell/tissue 
(represented here by epithelial cells) and the virion is transported along the axon to the cell body 
(soma) via retrograde transport. Bottom: Reactivation of alphaherpesvirus from latency. The virion 
travels via anterograde transport to a synapse where the virus infects post-synaptic cells (represented 
here by epithelial cells) lytically.  
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Neurotropism 
Unlike VZV, which can infect several regions of the CNS and result in a variety 
of CNS manifestations [197], HSV-1 and HSV-2 most often are associated with 
infection in distinct and different areas, i.e. they show a hitherto unexplained type-
specific neurotropism. In neonatal children, HSV-1 and HSV-2 can cause 
meningoencephalitis. In both manifestations, the brain and the meninges are 
involved, but the infection is less severe when HSV-1 is diagnosed [198]. 
When causing encephalitis in adults, HSV-1 preferably infects the limbic 
system and the temporal lobes. This infection results in severe damage including 
necrosis in the affected area [132]. Memories, language, olfaction, behaviour and 
emotions are functions associated with these regions of the brain, and the affected 
areas are often linked to neurological sequelae that can be life-long.  
In contrast, the meninges are the main target during HSV-2 infection of the 
CNS in adults [132]. Consisting of three membranes, the meninges surround and 
protect the brain and spinal cord, and infection leads to acute symptoms such as 
severe headache, neck pain and nuchal rigidity. Importantly, many of these 
patients develop recurrent meningitis [199]. In addition, focal symptoms such as 
urinary retention in patients with HSV-2 meningitis may be linked to myelitis in 
the lumbosacral region [200]. Despite such attacks, adults with primary and 
recurrent HSV-2 CNS infections of the CNS rarely display long lasting symptoms 
or permanent sequelae [201]. 
Alphaherpesvirus infections in the CNS 
Herpes simplex encephalitis 
HSE, with at least 95% of cases caused by HSV-1, is the most severe CNS 
infection caused by alphaherpesviruses in adults [202, 203]. HSE is seldom caused 
by HSV-2, but there are a few case reports connected to invasive surgery and brain 
trauma such as ischemic stroke [204, 205]. In addition, some few cases of HSV-2 
encephalitis have been presented without any concurrently inflicted brain trauma 
or underlying immunodeficient conditions [204, 206]. In some studies HSV-2 is 
reported to be involved in 10% of all HSE cases, but it is unclear from where this 
data originates, or if neonatal HSV CNS infection is included in this percentage. 
Closer to the truth is probably that HSV-1 causes most HSE cases after the 
neonatal period, based on the different neurotropism of the two viruses as 
described above. 
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 With an incidence of 2-4 cases per million inhabitants per year (Figure 11), 
HSE is the most common sporadic viral encephalitis in the Western world [140, 
207, 208]. Before the introduction of antivirals HSE was associated with a 70% 
mortality rate, but despite reduced mortality to around 10-20%, morbidity after 
antiviral treatment is still high, where the majority of patients are left with 
remaining neurological sequelae [207, 209-212].  
HSE can be caused either by primary or recurrent infection [203] and can occur 
in all age groups, although it is more common in elderly (Figure 11). Recurrent 
infection is likely if antibodies against HSV-1 are present at onset of neurological 
symptoms. This is the case for at least 2 of 3 HSE patients, both adults [203] and 
children [213]. However, it is unclear if the infection is due to reactivation of virus 
from the site of latency, activation of virus already in the brain or infection with a 
new, neurovirulent strain of the virus.  
On a cellular level, the infection in HSE patients is mainly found in the cerebral 
cortex [214, 215], which is the outer layer of neural tissue in the brain. The 
Figure 11. Top: HSE cases in Sweden between 2006-2014 [54]. Bottom: Age distribution of HSE in 
Sweden 1990-2001 (adapted from [207]). 
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composition of the cerebral cortex, the outer layer of neural tissue in the brain, is 
grey matter, which is selectively damaged in the infected regions [216]. 
Particularly, neurons in lamina V are affected (Figure 12).  
The suggested routes of entry for HSV-1 into the CNS are via either the 
olfactory tract or the trigeminal nerve (Figure 13), and both these routes have been 
described in the literature [214, 217, 218]. Interestingly, in an autopsy material 
from HSE patients that died early after onset, olfactory bulb infection was 
prominent [214].  
HSE usually engages the limbic system and the temporal lobes (Figure 13), 
where symptoms and sequelae are related to the extent and severity of damaged 
regions. Symptoms and sequelae include (although are not restricted to) focal 
neurological symptoms, memory loss, epilepsy and seizures, aggression, 
dysphasia and hemiparesis. In almost all HSE patients, lesions are detected in 
hippocampus, the region in the brain that is responsible for converting short-term 
memory to long-term memory. This has been reported by Damasio et al. [216], 
who describe an HSE patient with major amnesia syndrome due to extensive 
destruction of the temporal lobe and the limbic system. The patient experienced 
HSE ten years prior to the report, and had not since been able to acquire any new 
memories. Neither did the patient have any extensive recollection of memories 
prior to the infection.  
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To identify the areas affected by HSE, methods such as magnetic resonance 
imaging (MRI), computed tomography (CT) and electroencephalogram (EEG) are 
Figure 13. Top: The right 
side of the brain as seen from 
outside. Bottom: Cross-
section of the brain. The 
corpus callosum (larger) and 
the anterior commissure (AC; 
smaller) are bundles of nerve 
fibres connecting the two 
brain hemispheres and 
facilitating the 
communication between 
them. The two suggested 
points of entry for HSV-1 
into the brain are marked: the 
olfactory bulb and the 
trigeminal nerve. The 
location of the hippocampus 
is marked with a dark grey 
structure. 
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used. While MRI can detect pathological changes caused by HSE during the entire 
course of the infection, CT cannot always detect abnormal changes in initial 
infection [209, 220]. EEG is of particular importance to identify epilepsy in 
patients with decreased consciousness. The early finding by MRI and CT in HSE 
is oedema (Figure 14), and haemorrhages in the encephalitic area are also quite 
common. The presentation on neuroimaging may therefore mimic bleeding or 
acute cerebral infarction, although not systematically described hitherto [221] 
(Figure 15). Initially, the infection is unilateral, with herpetic lesions only being 
present in one brain hemisphere, but may spread to both hemispheres in the later 
stages of infection. As expected, herpetic lesions are found in the temporal lobe 
and the hippocampus, related to the neurological symptoms and sequelae seen in 
HSE patients (Figure 14). However, lesions can also involve the frontal, parietal 
and occipital lobes. 
In one study, increased intracranial pressure (ICP) which peaked at day 12 after 
onset of symptoms was reported for one third of all HSE patients [222].  
Figure 14. Left: MR scan in the acute stage from a 53-year-old woman with HSE and onset of 
disorientation on the day of admission. Six days after admission, coronal T2-weighted images show a 
widespread oedema in the ventromedial part of the right temporal lobe, dominating in the hippocampus 
region and in the right insula region. A minor oedema is seen in the left hippocampus region.  
Right: CT scan on the day of admission from a 58-year old woman with HSE with disorientation at 
arrival to hospital. An expansive low attenuated lesion in the right temporal is seen with an oedema in 
the temporal and parietal lobes. The appearance is concordant with HSE, but could be mistaken for 
low-grade astrocytoma. Published with permission [219]. 
Figure 15. CT scan without contrast in the acute stage from a 27-year-
old man with HSE with symptoms of fever, headache, and progressive 
disorientation during 10 days before admission to hospital. An 
expansive intracerebral haemorrhage in the insular region of the left 
temporal lobe is seen with a large oedema causing compressing of the 
left ventricle. 
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HSE is mainly affecting immunocompetent patients, but may also cause 
opportunistic infection in CNS in immunocompromised hosts [223]. In the latter 
group, the clinical findings often show a different picture (reviewed in [224]). 
These patients often present with an atypical infection pattern, where extensive 
involvement of other parts of the brain, including the cerebellum and the brain 
stem, are described. One study attributed this to the ineffective immune response 
in these patients, allowing the virus to spread more uncontrolled [225]. 
Furthermore, immunocompromised patients tend to present with fewer prodromal 
symptoms and less focal deficits than immunocompetent patients [225]. Non-
inflammatory CSF profiles and negative CT scans can also be seen; findings that 
have led to speculation that HSE might be underdiagnosed in 
immunocompromised patients due to difficulties in recognizing symptoms [223, 
226]. Despite reports of poor outcome [225], there have also been reports of 
patients who have recovered from HSE, despite their immune deficient state, 
without neurological sequelae [227].  
Occasionally, HSE patients can have clinical relapses, which can be either a 
“true” relapse (where HSV DNA can be detected in the CSF) or an immune-
mediated relapse (where no HSV DNA can be found in the CSF) [228-231]. HSE 
relapses often occur within a few weeks to months of discontinuation of antiviral 
therapy and immune-suppressant drugs are administered since immune-mediated 
mechanisms are suggested [228].  
Neonatal HSV infections in the CNS  
Unlike HSE, neonatal meningoencephalitis caused by HSV has less distinct 
distribution of virus and more extensive involvement of other parts of the brain. 
HSV-infections in neonates most often result from a transmission from an 
infected mother to the baby and can be acquired at three stages: congenitally (in 
the uterus), perinatally (during delivery) or postnatally (after delivery) [39]. 
Perinatal transmission is the most common and can occur during delivery when 
the baby may come in direct contact with infected vaginal secretions. In mothers 
with primary infection close to delivery date, the risk for transmission of virus to 
the baby is increased compared with mothers with established HSV infection 
(reviewed in [232]).  
The three forms of neonatal HSV infection, CNS infection, multi-organ 
disseminated disease and disease located in skin, eye or mouth (SEM), differ 
slightly in incidence and prognosis [233]. In Sweden, the incidence of neonatal 
HSV infection is approximately 1:12 000 to 1:13 000 births [234], while in the US 
the incidence is much higher [232]. 
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Initially, the symptoms of neonatal CNS infection are non-specific, and can 
include fluctuations in body temperature, apathy, respiratory distress and feeding 
difficulties, which can later develop into apnoea, disseminated intravascular 
coagulation, hypotension and shock. In approximately two-thirds of all neonatal 
HSV CNS infections, skin lesions can be found. CT scans of neonatal CNS 
infection have revealed abnormalities in 55-65% of the cases [235], which could 
be localised to the temporal, frontal, parietal and subcortical regions. 
While antiviral treatment has reduced the mortality in early HSV infection of 
the CNS, morbidity is still high, especially for HSV-2, which unfortunately is the 
most common cause in neonates (approximately 75-80% of all cases [198]). Many 
HSV-2 infected neonates show residual neurological sequelae or die after 
infection, while HSV-1 infected neonates in one study totally lacked sequelae at 
follow-up [198]. Despite the reportedly better outcome for neonates infected with 
HSV-1 as compared with those infected with HSV-2, there has been reports of 
neurological sequelae and mental retardation in long-time follow-up studies also 
after neonatal HSV-1 CNS infection [234, 236]. 
The morbidity can include delays in development, epilepsy, blindness, cerebral 
palsy and cognitive disabilities [198, 234]. Furthermore, microcephaly has been 
reported after neonatal CNS-infection, as well as after congenitally acquired 
infections [43, 198, 235, 236], a finding which also has been described for other 
viral infections such as rubella virus [237, 238] and more recently Zika virus [239, 
240].  
Herpes simplex meningitis 
While HSE carries a high mortality rate, herpes simplex meningitis (HSM) has 
a milder course, where most patients recover within weeks to months. HSV-2 is 
the main cause of HSM, although a few cases are attributed to HSV-1 [145]. In 
primary HSV-2 meningitis, symptoms such as intense headache, neck stiffness, 
photophobia and nausea can be observed [241]. These symptoms are similar to 
what is found for bacterial meningitis, but the viral meningitis is less severe. 
Furthermore, around 30-40% of all HSM patients are reported to experience 
symptoms from the central, peripheral and/or autonomous nervous system [242]. 
Herpetic lesions may precede or occur in association with the HSM, but more than 
half of the patients report of no previous or current herpetic lesions.  
Most patients suffering from HSM will not experience any long lasting 
complications, but 20-30% of all patients develop recurrent meningitis episodes. 
These episodes usually have a shorter duration than the primary episode and 
milder symptoms. HSV DNA can be detected and quantified by real-time PCR in 
the CSF in most cases. Immunocompromised patients are more prone to develop 
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neurological sequelae or even fatal meningoencephalitis if they do not receive 
treatment in early infection [201, 243].  
 HSM is responsible for almost 20% of all viral meningitis in Sweden, where 
most cases are found among younger adults [143]. Interestingly, the incidence of 
HSM is considerably higher in female patients than in male subjects [241, 244, 
245]. This might be attributed to the larger area involved in the genital HSV 
lesions of women, and that a higher proportion of patients from this gender 
experience viraemia, and at a higher dose, during primary HSV-2 infection [246]. 
It has been observed that pre-existing antibodies against HSV-1 may protect 
against HSM caused by HSV-2 [242], similar to the reported asymptomatic genital 
infections of HSV-2 in patients with pre-existing HSV-1 antibodies [247]. 
Mollaret’s meningitis 
 Mollaret´s meningitis is a rare type of recurrent meningitis in which recurring 
aseptic meningitis occurs over several years and even decades. Patients experience 
recurrent episodes of headache, stiff neck, fever and CSF pleocytosis [248]. These 
episodes normally resolve after 2-5 days and the duration between episodes can 
vary from a few weeks to several years (reviewed in [249]). Although diagnostic 
evidence has not been found in all described cases, HSV-2 DNA [250] is often 
detected in CSF and this virus has been suggested to be the most common 
causative agent.  
Varicella zoster CNS infections 
As mentioned previously, VZV can cause a wide spectrum of CNS infections 
of diverse severity, and with a more scarcely documented occurrence of 
neurological sequelae as compared with HSV infections [132]. Adults with 
reactivated VZV (zoster infection) are more common as a trigger for neurological 
disease, but acute VZV infection (varicella) can also be complicated by CNS 
manifestations [132]. In children, the infections are often diagnosed in association 
with vesicular rash, however reactivation of the virus is not necessarily 
accompanied by skin lesions. Several of the CNS manifestations caused by VZV 
infections, as described below, can also be observed in patients with active HSV-
infection, but are less common. Furthermore, some of the described CNS 
manifestations may occur simultaneously. 
 
Due to its appearance in association with either primary infection or 
reactivation as zoster, VZV encephalitis is most commonly diagnosed in elderly 
immunocompetent persons [157]. In the AIDS-era, the prevalence of encephalitis 
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due to VZV has been increased, but other causes of immunosuppression can 
contribute to this complication, where it is found regardless of age [251]. In a 
small retrospective study of VZV encephalitis cases in France, it was found that 
despite antiviral treatment, mortality and morbidity rates were similar to those 
seen in antiviral-treated HSE [252]. Parallel findings have also been seen in 
Swedish patients [157] and have been presented by others in follow-up studies 
[144], although these reports also included encephalitis cases caused by other viral 
agents. The neurological sequelae after VZV encephalitis tend to be subcortical, 
where cognitive processes, memory, emotions and behaviour have reportedly been 
affected (reviewed in [197]). 
 
VZV cerebellitis, in the form of acute cerebellar ataxia (ACA) is a type of 
encephalitis that affects the cerebellum, and is mainly seen in young children 
within three weeks of primary infection [253]. ACA affects the coordination of 
muscle movement and in particular balance, coordination, and eye movements. 
Besides its known motor functions, cerebellum has also influence on non-motor 
regions of the cerebral cortex (reviewed in [254]) suggesting a role in cognition, 
which may also be affected by ACA [253]. Furthermore, nausea and headaches 
can also occur [197]. Some studies report of patients recovering fully within a few 
months [255, 256], while other studies describe remaining sequelae in some 
patients [253]. 
 
VZV brainstem encephalitis is a special form of encephalitis where the 
brainstem is affected. The brainstem, adjacent to the spinal cord, normally controls 
vital life functions, including respiration, cardiovascular control and 
consciousness, and infection here may lead to serious consequences.  
 
VZV meningitis can occur in all age groups [132]. Meningitis caused by VZV 
is mainly due to zoster reactivation. Furthermore, reactivation of the VZV vaccine 
strain in immunocompetent children has been reported to cause meningitis [257]. 
Most patients, irrespective of age, experience a favourable outcome after VZV 
meningitis, with no or mild neurological sequelae. 
  
VZV can also cause meningoencephalitis, which, like VZV encephalitis, is 
more common in older patients [132]. Dysfunctions in the brain (without 
diagnosed encephalitis) that can lead to paresis, motor deficits or altered 
consciousness, can be due to VZV encephalopathy [157].  
 
  Ramsay-Hunt syndrome is a complication of VZV reactivation in the 
geniculate ganglion (a bundle of nerve fibres and sensory neurons of the facial 
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nerve) [157, 258]. Ramsay-Hunt syndrome is normally unilateral, and is mainly 
seen in older age groups. Patients commonly present with vesicular (zoster) rash 
in the ear, along with other ear-associated symptoms like ear pain, vertigo, tinnitus 
and hearing loss. Furthermore, acute paralysis of the facial nerve develops and is 
an important part of the syndrome. Despite reactivation of virus, lesions are not 
always found, which can hamper diagnosis. Without antiviral treatment, only 10-
20% of all patients fully recover and even with treatment, 40% show rest 
symptoms. In the CSF, a pattern of increased biomarkers for neuronal damage and 
astrogliosis was recently found, and the amounts of these factors correlated to the 
detected VZV DNA quantities [259]. Hence, it was suggested that early 
diagnostics and start of treatment during Ramsay-Hunt syndrome is of importance 
for the outcome.  
 
Myelitis is an infection of the white or grey matter in the spinal cord that can 
result in paresis of extremities, reduced functions in bladder or bowel or sensory 
deficit, depending on which nerve roots that are affected by VZV. 
Immunocompromised patients are overrepresented in the VZV myelitis cases, and 
reportedly the outcome is worse, with higher mortality or degree of disability, 
compared with immunocompetent patients (reviewed in [260]). Another infection 
close to the spinal cord is radiculitis, which is an inflammation of the spinal nerve 
roots combined with severe pain along the associated nerve [261]. 
 
CNS vasculopathies can be caused by VZV in both children and adults. Large 
or small cerebral arteries can be infected with VZV, which can predispose for 
brain haemorrhage, aneurysms or ischemic stroke. It is thought that VZV 
vasculopathy might be underdiagnosed (reviewed in [197]) especially in the 
elderly population where the CSF of stroke patients seldom is analysed for signs 
of recent VZV infection. In contrast to what is seen for HSE, some researchers 
have suggested that VZV encephalitis is caused primarily by vasculopathy rather 
than by direct infection of the brain [262, 263], but this question remains to be 
resolved.  
2.4 Immune responses in the CNS 
The CNS is normally protected from direct entry of pathogens by the BBB. 
Furthermore, microglia are a type of glial cells that function as the initial form of 
active immune defence in the CNS and they are also known as the residential 
macrophage cells. Microglia are very sensitive even to minimal pathological 
changes in the CNS and are active both in the search for damaged neurons and 
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synapses, plaques and pathogens (reviewed in [264]). Due to the sensitivity of the 
nervous tissue in the CNS, microglia are required to act quickly both to decrease 
inflammation and neuronal damage and to destroy the invading pathogen. To be 
activated and to communicate with other CNS cells and immune cells, microglia 
can be assisted by different parts of the innate immune response, where cytokines 
are very important [264]. Microglia have also been reported to be involved in 
neuroinflammation and neurodegeneration, where different pro-inflammatory 
factors may put microglia in a continuous active state [265, 266].  
Antibody response 
Antibodies are proteins secreted by B-cells that can recognize and identify 
pathogens. To bind antigens, the antibody has a Y-shaped form, where the tail 
region (known as the fragment crystallisable (Fc) region) can interact with Fc-
receptors on cell surfaces or with proteins of the complement system to alert the 
immune system of pathogens, thereby activating it [3].  
There are five different classes of antibodies, IgA, IgD, IgE, IgG and IgM, of 
which IgG and IgM are of particular interest in viral CNS infections. Depending 
on cell developmental stage and activation, different classes are produced by 
different types of B-cells. IgM is an early participant in the B-cell mediated 
immune response to pathogens, before IgG is produced (Figure 16). Class 
switching and maturation of the antibody response is required for generation of 
IgG [3] and this antibody is thus a part of the secondary immune response. In early 
primary infection, levels of IgM are high, and levels of IgG do not increase until 
later in infection (Figure 16). IgG can usually be detected also after primary 
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infection, which is used in serology to confirm a diagnosis retrospectively. At a 
second exposure to the antigen, the IgG response normally is higher, as B-cells 
producing antibodies against the antigen already circulate in the body (Figure 16).  
Interestingly, intrathecal antibodies in the form of IgG against HSV can be 
found many years after HSE, a finding not reported for any of the other 
alphaherpesvirus CNS infections [267, 268]. 
The complement system 
The complement system is an important part of the innate immune response, 
which has pro-inflammatory, immune enhancing and cell membrane-attacking 
features. The major production of complement components, which include fluid-
phase proteins and cell-surface receptors, occurs in the liver, but there have also 
been reports of a separate production in the CNS, both by glial cells and neurons 
(reviewed in [269, 270]). It is not so surprising that the CNS has separate synthesis 
of complement components, given the separation of the CNS from the general 
circulation via the BBB, which hinders the passage of larger proteins. 
Activation of the complement system both leads to release of anaphylatoxins 
(peptides with pro-inflammatory features) and to the formation of the membrane 
attack complex (MAC) which results in membrane disruption. Complement 
activation mainly occurs via three different pathways: the classical pathway, the 
lectin pathway and the alternative pathway. In addition to these, other activation 
pathways have been identified in the more recent years, including activation of 
complement component 5 (C5) via thrombin [271] and via properdin (reviewed in 
[272]).  
The classical pathway is activated by antigen-antibody complexes, where 
antigen bound to both IgM and certain IgG isotypes are recognized by and interact 
with C1q. Binding to C1q (in a complex with C1r and C1s) triggers activation of 
two associated serine proteases that in turn cleave C4. Binding of C2 to C4b and 
a second cleavage then result in the formation of C4b2a, the C3 convertase of the 
classical and lectin pathway (Figure 17).  
The lectin pathway is initiated by pattern recognition receptors such as 
mannose-binding lectin (MBL). Invading microorganisms and foreign cells are 
recognized by MBL via carbohydrate patterns on their surface. Binding to this 
surface activates the MBL-associated serine proteases, which then proceed to 
cleave C4 and eventually leads to the formation of C4b2a (Figure 17).  
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The alternative pathway is separated from the two other pathways in that it 
produces another C3 convertase: C3bBb. Furthermore, the alternative pathway 
does not require binding to an antibody or pathogen for activation. Rather, 
activation occurs via spontaneous breakdown of C3 to C3a and C3b (or C3-H2O). 
C3b is bound to complement factor B (CFB), which is then cleaved by the serine 
protease factor D, followed by binding of properdin and the alternative C3 
convertase is formed (Figure 17). 
Figure 17. The three major activation 
pathways of the complement system and 
the terminal pathway. 
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Both of the C3 convertases can cleave C3 to C3a and C3b, where C3b then can 
attach covalently to target surfaces. C3b can also bind to the C3 convertases, 
leading to the terminal pathway. Here, the convertase specificity changes from C3 
to C5, where C5 cleavage results in production of C5a and C5b. The C6-C9 
components then bind to C5b, resulting in the formation of the MAC and 
membrane disruption.  
The anaphylatoxins C3a and C5a are released during complement activation 
and can interact with specific receptors to stimulate both the innate and the 
adaptive immune response. C4a is also accounted as an anaphylatoxin, but is much 
weaker than C3a and C5a, and its actions and significance have not yet been 
elucidated [273].  
While the complement system is important for targeting and eliminating 
pathogens, it has also been reported to have a negative role in demyelinating and 
neurodegenerative diseases, like multiple sclerosis (MS) [274], Parkinson’s 
disease [275, 276] and Alzheimer’s disease [277]. The negative role of the 
complement system on these conditions may be mediated through a long-term 
immune response that attacks the cells of the brain, leading to cell damage. The 
negative effects of the complement system have mainly been attributed to over-
activity of the anaphylatoxins, which have pro-inflammatory features and recruit 
inflammatory cells to the area (reviewed in [278, 279]).  
The importance of the complement system in CNS infections has only recently 
come into focus, where bacterial meningitis has been more extensively examined 
than viral CNS infections [280-283]. In bacterial meningitis, increased activity of 
different complement components is associated with positive or negative outcome 
depending on the specific pathogen that is involved [284]. Furthermore, in vitro 
studies indicate that neuronal cells are less susceptible to complement attacks than 
are skin cells, suggesting a contribution to the latency of HSV-1 in neurons [285]. 
Complement component 3b can bind to glycoprotein C of HSV-1 
As described earlier gC-1, but not gC-2, functions as a receptor for C3b on 
whole virions [124, 286]. The C3b-binding activity of gC-1 has been suggested to 
have a protective effect for the virus on antibody-independent immune activation 
and neutralization. It has been shown that while gC-deficient HSV-1 and HSV-2 
strains are neutralized by the complement system, regardless of presence of anti-
HSV-antibodies, the infectivity of wild-type strains with fully functioning gC-
regions is unaffected in the presence of complement components.  
Binding of C3b to wild-type gC-1 induces blocking of other members of the 
complement cascade, which includes properdin and C5 [287]. As shown in Figure 
18, properdin functions as a stabilizer of the C3 convertase of the alternative 
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pathway. Therefore, inhibition of properdin binding to C3b would protect HSV-1 
from complement-mediated lysis via the alternative pathway. Interestingly, the 
properdin-binding property of gC-1 is not found for gC-2, not even in its purified 
form [129, 287]. As interactions between properdin and the mucin-like region of 
gC-1 have been demonstrated [126], a region missing in gC-2, these results are 
not surprising. Furthermore, the mucin-like region also appears to interfere with 
the binding of C5 to C3b [287]. No reduced effect on lysis via the classical 
pathway has been reported in studies [288]. As activation of the alternative 
pathway does not require antibody binding, the complement blocking effect of 
gC-1 might be most important early in HSV-1 infection, as has also been 
suggested by Friedman et al. [289].  
Interestingly, the mab B1C1, recognizing the amino-terminal loop structure of 
the gC-1 protein, has been shown to reduce the complex of C3b, properdin and 
C5, indicating that the GAG-binding structures of gC-1 also are important for C3b 
binding [125]. All in all, the interactions of gC-1 with C3b, properdin and C5 
indicate the importance of complement blocking for HSV-1 immune evasion.  
Toll-like receptors 
 Like the complement system, toll-like receptors (TLRs) are an important part 
of the innate immune response. Expressed on the membranes of leukocytes, 
fibroblasts, epithelial cells, glial cells and endothelial cells and within endosomes, 
TLRs are single membrane-spanning receptors that recognizes structurally 
conserved molecules from microorganisms [291-293]. Through the recognition, 
TLRs activate immune cells by recruiting adapter proteins, in order to increase the 
antigen-induced downstream pathways and subsequent activation of other 
Figure 18. Left: The four regions of wild-type gC-1 involved in binding to C3b (region I-IV) and 
the mucin-like region (Δ33-123) blocking binding of properdin (P) and C5. Right: Binding of P and 
C5 to C3b in a mucin-like region deficient gC-1 mutant. The deficient gC-1 mutant is similar in 
structure to gC-2, which also lack the mucin-like region Adapted from [290]. 
C3b
P
C5
I
II
III
IVΔ3
3-
12
3 gC-1
Cell surface
C3bP
C5
I
II
III
IV
gC-1
Cell surface
Wildtype gC-1 gC-1 deficient in mucin-like region
 
40  C HAR LOTT A ER IKSSON  
downstream proteins including protein kinases and cytokines, leading to cell 
proliferation and increase in adaptive immunity [292].  
 TLRs can be found in the CNS, where they participate in the innate immune 
response against pathogens, as they do in the rest of the body. However, studies 
have also indicated negative effects of TLRs in the CNS, where they participate 
in autoimmunity, neurodegeneration and tissue damage [291].  
 Several TLRs have been reported to be involved in HSV-infection. Cell 
expression of TLR3 and TLR9, among others, have been of interest in HSV-
induced CNS infections, where increased responses have been noted [294]. 
Although few host mutations have been found to increase the risk for 
alphaherpesvirus CNS infections, deficiencies in TLR3 have been shown to 
increase the risk for HSE in otherwise healthy children [19, 295, 296]. However, 
only about 5-10% of all cases of HSE in children can be related to TLR3 
mutations. One case report describes a TLR3-related mutation in a young adult 
HSE patient [18] and a recent study identified TLR3-related mutations in adult 
HSE patients [297]. These reports indicate that deficiencies in the TLR3 pathway 
might also increase susceptibility to HSE in adults. Hence, TLR-3 mediated 
immune response may be of importance in the control of HSV infection in the 
CNS.  
Cytokines 
 Cytokines are a category of small cell-signalling proteins which play an 
important role in immunomodulation through their effects on surrounding cells 
[298]. Their actions are mediated via receptors where they modulate the balance 
between the humoral and the cell-based immune response, and also regulate the 
maturation, growth and responsiveness of certain cell populations. Furthermore, 
some cytokines can influence the actions of other cytokines via a signalling 
cascade [299]. Cytokines are produced by numerous cell types; macrophages 
(including microglia), B-lymphocytes, T lymphocytes, mast cells, endothelial 
cells, fibroblasts and other connective tissue cells [300]. Chemokines, interferons 
(IFNs), interleukins (ILs), lymphokines and tumour necrosis factor (TNF) all 
belong to the cytokine group, where a specific cytokine can be produced by more 
than one cell type. Pro-inflammatory cytokines, such as IFNs, ILs and chemokines 
can be induced by oxidative stress and can be induced by and contribute to 
oxidative stress [301].  
 Cytokines all have matching cell-surface receptors, where binding leads to 
intracellular signalling cascades that can alter different cell functions, including 
upregulation and downregulation of several genes and their corresponding 
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transcription factors. This in turn can induce production of other cytokines, 
increase the production of surface receptors for other molecules, or suppress their 
own effect through a feedback inhibition loop [298].  
 Interestingly, apart from their immune-modulating properties, cytokines have 
been shown to be involved in several developmental processes during 
embryogenesis (reviewed in [302, 303]).  
 In the CNS, cytokines assist in activating microglia and in stimulating the 
adaptive immune response [300].  
Although cytokines are important in the immune response to infections, they can 
also promote pathological changes in our bodies. Such adverse events have been 
linked to different disease entities including schizophrenia, major depression and 
Alzheimer’s disease [300, 304]. Pro-inflammatory cytokines are also reported to 
contribute to the continuously active state of microglia in CNS during infections 
and inflammation, which can result in neurodegeneration [305]. Furthermore, 
over-secretion of cytokines can trigger a cytokine storm (or hypercytokinemia) 
which is a potentially fatal immune reaction where the usual regulatory feedback 
loop between cytokines and leukocytes is disturbed [299]. A cytokine storm 
leads to over-activity of immune cells in a specific area in the body, and such 
activity can cause extensive damage to tissues and organs in this area. The cause 
of a cytokine storm is still not elucidated, but it has been suggested that an 
exaggerated immune response occurs when a new and highly virulent pathogen 
invades the host. Interestingly, cytokine storms have been connected to 
numerous viral infections, including Ebola [306-308], avian influenza [309] and 
smallpox [310]. The extensive effects of the 1918 pandemic on the younger 
population are believed to be due to the stronger immune response in a healthy 
immune system, thereby leading to increased cytokine levels [311]. 
Interferon gamma 
 As the only member of the type II class of interferons, IFN-γ is critical for both 
the innate and the adaptive immune activity against viral, bacterial and protozoal 
infections [312]. IFN-γ is secreted by T helper cells type 1 (Th1 cells), cytotoxic 
T cells and NK cells, and has both antiviral and immune-regulatory properties 
[312]. Furthermore, secretion of IFN-γ from Th1 cells results in a positive 
feedback loop that promotes CD4+ differentiation to Th1 cells. In the CNS, IFN-
γ can also activate microglial cells, which then results in a cytokine-induced 
cascade that activates surrounding microglia. In response to IFN-γ activity, NK-
cell and macrophage activity is promoted, along with expression of major 
histocompatibility complexes (MHCs), and induction of intrinsic defence factors 
leading to direct antiviral effects [312]. 
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 IFN-γ normally binds to the heterodimer interferon-γ receptor, leading to 
activation of cellular responses [312]. IFN-γ can also bind to HS, one of the 
receptors HSV may use to enter a cell. The biological significance for interaction 
between HS and IFN-γ is not extensively described, although it has been suggested 
that this interaction with HS may protect IFN-γ from proteolytic cleavage [313].  
 Interestingly, increased IFN-γ production has been found in the acute phase of 
HSE [314, 315]. In animal models, deficient IFN-γ production has been connected 
to a poor outcome after HSV infection, associated with increased apoptosis [316]. 
When IFN-γ instead is present, neuronal death is reduced, indicating the protective 
role for this cytokine in HSV infection. However, in patient studies it has been 
shown that higher initial values of IFN-γ in HSE are related to a poor outcome 
[315].  
 In connection with deficiencies in IFN-α and IFN-β, impaired production of 
IFN-γ has been shown to increase vulnerability for viral infections, including the 
risk for HSE (reviewed in [317]). Therefore, it might be inadvisable to completely 
block the production of IFN-γ during the initial phase of HSE. 
Tumour necrosis factor alpha 
 TNF-α is mainly produced by activated macrophages, but other immune cells, 
as well as glial cells and neurons, can also contribute to TNF-α production [318, 
319]. As a part of the so-called acute phase reaction, TNF-α regulates immune 
cells, but this cytokine can also induce apoptosis, inflammation and inhibit viral 
replication [318]. For cell signalling, TNF-α can bind two receptors: TNF receptor 
type 1 (TNFR1) and TNF receptor type 2 (TNFR2). While TNFR1 is expressed 
in most cells, TNFR2 is mainly express in cells of the immune system [318]. 
Furthermore, the receptor types respond differently to different trimeric forms of 
TNF-α, where the role of TNFR2 has been less extensively examined [318].  
 In HSE, levels of TNF-α have been shown to peak not in acute infection but 
rather during early convalescence [314]. TNF-α has been shown to be toxic to 
myelin, which could contribute to the damage seen in CNS in HSE patients. 
Furthermore, several other diseases, including Alzheimer’s disease, cancer and 
depression have been connected to dysregulation in TNF-α production, either 
through mutations or through anti-TNF-α treatment via monoclonal antibodies.  
Aquaporins 
Aquaporins constitute a family of membrane-bound water channels, whose 
function is to form pores in the cell membrane to enable rapid transport of water 
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through cells while preventing passage of ions. The transport of water over 
membranes is needed in order to maintain the osmotic balance in the cell. Some 
aquaporins only transport water across the cell membrane, while other aquaporins 
with larger-sized pores also can transport small, uncharged solutes like urea, 
glycerol, ammonia and CO2 and are known as aquaglyceroporins. The human 
aquaporins AQP3, AQP7, AQP9 and AQP10 belong to this group. 
In the cell membrane, aquaporins form tetramers, where the separate 
monomers all act as water channels. The aquaporin proteins consist of six 
transmembrane α-helices, which have both the amino end and the carboxyl end of 
the sequence located in the cytoplasm (Figure 19). To date, thirteen types of 
aquaporins are known and defined in mammals, but more are suspected to exist. 
The aquaporins differ from each other in their peptide sequences, and these 
sequence variations result in different pore sizes. 
In the brain, three main aquaporins are reported to function in the brain: AQP1, 
AQP4 and AQP9. AQP1 is mainly found in the choroid plexus cells [320, 321], 
suggesting a role for AQP1 in CSF formation, and has also been described in 
neurons in the trigeminal sensory ganglia [322]. Presence of AQP9 has been 
reported in astrocytes [322-325], vessel-lining endothelial cells [325] and 
catecholaminergic neurons [325-327], but these studies are mostly from animal 
models. Nevertheless, the function of AQP9 to transport solutes like glycerol also 
suggests a contribution to the cell metabolism [323]. AQP4 is the most abundant 
aquaporin in the brain, and also the most well studied. It can be found in astrocytes 
throughout the brain, although the distribution varies in different brain structures, 
which could suggest that AQP4 may have further physiological functions apart 
from water homeostasis (reviewed in [328, 329]). Furthermore, AQP4 has been 
extensively examined in relation to neuroinflammation in neuromyelitis optica, 
where auto-AQP4- antibodies can be found in serum of these patients [330-332] 
Due to their water transporting function, the CNS aquaporins not only regulate 
the brain fluid homeostasis but are also suggested to play a role in brain trauma 
Figure 19. The six-transmembrane α-helices of an aquaporin.  
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and brain oedema, contributing both positively and negatively to the water 
homeostasis (reviewed in [328]). Furthermore, AQP4 and AQP1 has been 
suggested to be involved in the pathogenesis of HSE [333]. 
Autophagy 
 With the Nobel Prize in Medicine 2016 awarded to studies of autophagy, it is 
difficult to discuss immune activity in CNS infections without referring to this 
process that the cell can use to eliminate dysfunctional components or unwanted 
cargo [335, 336]. Autophagy occurs when a double-membrane vesicle (known as 
an autophagosome) absorbs either a part of the cytosol or ubiquitinylated cargo 
(including pathogens – a process known as xenophagy). The autophagosome then 
fuses with the lysosome where lysosomal enzymes can degrade the cargo (Figure 
20).  
 Post-mitotic neurons, which cannot easily rely on cell-destructive or 
inflammatory responses due to the risk for neuronal death and neurodegeneration, 
have been shown to depend on autophagy instead to control intracellular 
Figure 20. Left: Impact of autophagy on viral infection in neurons. The virus is absorbed in an 
autophagosome (a double membrane vesicle) which then fuses with a lysosome, where the virus is 
degraded. This leads to decreased viral replication and production of interferon type 1, resulting in an 
overall increased neuronal survival. Right: Impact of viral infection on neuronal autophagy. When 
viral autophagy is inhibited, the viral replication is increased resulting in neuronal cell death via 
neurodegeneration and inflammation. Adapted from Orvedahl and Levine [334]. 
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pathogens such as viruses. Furthermore, autophagy is necessary for neuronal 
differentiation and homeostasis as well as prevention of neuronal cell death.  
Autophagy has been suggested to play a vital role in neuronal control of HSV 
infections, although the exact mechanisms are unclear. A recent study has 
suggested that autophagy, rather than IFN signalling, could dominate in the 
neuronal anti-HSV response [337]. In addition, it was demonstrated that 
autophagy was required to control HSV replication in neurons, unlike what was 
seen in mitotic cells [338, 339]. Furthermore, another study has demonstrated 
upregulation of autophagic clusters during HSV infection, but mainly in neurons 
that did not exhibit viral antigen expression [340].  
HSV can respond to autophagy via HSV-encoded autophagy-modulating 
proteins, such as ICP34.5. This evasion is important for establishment of 
encephalitis, where the prevention of neurodegeneration via autophagy is 
inhibited (Figure 20) (reviewed in [334]). This also suggests that the balance 
between latency and lytic replication in neurons is related to autophagy.  
Anti-N-methyl D-aspartate receptor encephalitis 
One type of encephalitis that has come into focus in recent years is the 
autoimmune anti-N-methyl D-aspartate receptor (NMDAR) encephalitis [341]. 
NMDARs are ligand-gated cation channels found on the cell membrane of 
neurons, and they are important in synaptic transmission and plasticity [342]. 
During anti-NMDAR encephalitis, NMDAR antibodies reduce the expression of 
glutamate receptors on neurons in post-synaptic dendrites [341].  
Anti-NMDAR encephalitis, which can present with seizures, autonomic 
dysfunction, abnormal or involuntary movement and changes in psychiatric 
behaviour, have mortality and morbidity rates (25% in total [343]) that are lower 
than those for HSE. The aetiology of anti-NMDAR encephalitis is not yet entirely 
known, although in approximately half of the cases malignancies are present [341, 
344]. However, a link between relapsing HSE and anti-NMDAR antibodies has 
been presented in recent years [345, 346], and there have also been reports of 
possible connections between anti-NMDAR antibodies and CNS infections by 
VZV [347] or morbilli virus [348]. In some anti-NMDAR encephalitis cases the 
autoimmune activity is suggested to be triggered by viral infection. Furthermore, 
a pathogenic effect on neurons has been reported for NMDAR antibodies [349] 
and while this could explain the sequelae seen in HSE patients, another hypothesis 
suggests that the neuronal damage developed during HSE provides a setting for 
development of NMDAR antibodies, without actually being an anti-NMDAR 
encephalitis.  
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Relationship between neurological sequelae and immune system 
activity in CNS infections 
 Although alphaherpesvirus infections in CNS can directly attack and kill 
various neuronal cells, findings described in this subchapter imply that the 
immune system activity itself can inflict damage on brain tissue. Studahl et al. 
[350] described increased levels of neurofilament in the CSF of HSE patients also 
on follow-up. As neurofilament is a sign of neuronal lysis, the immune system 
must be active also after the elimination of lytic HSV infection in the brain, 
thereby damaging the infected area further through neuroinflammation and 
neurodegeneration.  
 That alphaherpesviruses can persist in the neurons in a latent state without 
damaging the cells is in fact quite logical. These viruses does not benefit from 
attracting the immune defence, which would lead to apoptosis and immune 
activity, and instead the post-mitotic neurons are necessary for viral replication 
during reactivation. 
2.5 Diagnostic methods in alphaherpesvirus CNS 
infections 
For diagnostics of alphaherpesvirus CNS infections, quantitative polymerase 
chain reaction (qPCR) on CSF to detect viral DNA is the gold standard. In qPCR, 
a set of primers and a probe target a conserved sequence of the genome that will 
be amplified and quantified.  
qPCR as a diagnostic procedure can be used in the acute phase of the CNS 
infection, where virus usually can be detected in CSF in the initial phase of CNS 
disease and up to one-two weeks after onset of disease. However, PCR cannot be 
used in later stages of the infection, and in recurrent episodes of for example HSM, 
viral DNA is not always detectable. Furthermore, at least in HSE, PCR results 
may be negative for HSV in the beginning of the infection (days 1-3), but a second 
CSF sample taken a few days later might confirm the diagnosis [351, 352]. 
In later stages of infection, serology to identify antibodies in CSF and serum 
samples can be used to demonstrate intrathecal synthesis of IgG specific for the 
different alphaherpesvirus antibodies. The sensitivity of the serological tests 
increases with time. Acute infection can be diagnosed with elevated IgM levels in 
serum or seroconversion from negative to positive (where an antibody levels in an 
early sample are compared with those in a later sample). Intrathecal antibody 
production can also be analysed, by calculating the ratio between IgG levels in 
serum and in CSF, where increased levels indicate ongoing infection.  
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For neonatal HSV infection, PCR on material from herpetic lesions, serum, 
CSF and conjunctival swabs are used. Positive PCR findings are valid for 
diagnostics in new-borns during their first month. It has been demonstrated that 
uninfected new-borns can present with positive IgG levels from a mother who has 
experienced HSV infection during the perinatal period, due to maternal antibodies 
delivered across the placenta [353].  
2.6 Vaccines and treatment in alphaherpesvirus 
CNS infections 
Vaccines 
 Out of the three human alphaherpesviruses, vaccination is currently only 
available for VZV. A live varicella vaccine (Varilrix® or Varivax®) has been 
available for around 20 years and is mainly given to children to prevent varicella 
infection. Several countries around the world, including USA and Germany, have 
childhood vaccination programs including varicella [354, 355]. In Sweden 
however, although varicella vaccine is available, the government has not yet 
decided to include it in the general childhood vaccination program [356]. The 
existing varicella vaccine is a live attenuated vaccine based on a clinical VZV 
isolate, the Oka strain [357]. Vaccination induces VZV-specific cellular immunity 
and primes the host response, which modify the severity of the disease. Although 
one dose of the vaccine to children reportedly induces cellular immunity in more 
than 90% of all recipients, a second dose is even more efficient. In addition, due 
to fear of severe primary VZV infection during pregnancy and 
immunosuppression, this vaccination is also available for adults. In these patients, 
two doses of the vaccine need to be administered to achieve high rates of 
seroconversion. However, despite the two-times administration of the vaccine, 
adults have lower cellular immunity to VZV and lower IFN-γ response compared 
with children that only have received one dose of vaccination.  
 In at least 94% of vaccine recipients, the VZV IgG and T-cell responses is 
persistent for 7 to 10 years after immunisation. However, long-term VZV immune 
evaluation has not been performed following vaccination, and it is unclear if 
booster doses are needed. The incidence of CNS complications associated with 
varicella has been reduced in countries where varicella vaccination is 
recommended [256]. This is related to the successful protection against primary 
infection, but whether this vaccine will protect also against reactivated VZV 
infections in adults is still an open question. Vaccine-related reactivation of VZV 
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has been described in a few cases of immunocompetent recipients, but reactivation 
of vaccine virus in recipients with suppressed immunity is reported to occur less 
often than wild-type VZV reactivation in unimmunised patients.  
Moreover, a high-dose version of the live vaccine (Zostavax®) is available for 
prevention of herpes zoster, and is given to the older population to prevent 
reactivation during waning immunity. Here, a higher dose than that administered 
to children is needed, but the protection against zoster and PHN is limited [358]. 
The vaccine decreased the incidence of zoster by 51.3% (p<0.001) compared with 
placebo recipients, and the incidence of PHN was decreased by 66.5% [358]. This 
data indicates the need for a new or improved zoster vaccine. 
Recently, promising data from phase 3 clinical trials regarding protection 
against zoster was reported for a subcomponent vaccine based only on VZV 
glycoprotein E (gE) [359, 360]; this vaccine will probably reach the market in 
2017. Selection of gE as the candidate antigen was based on the knowledge that 
gE is essential for replication and cell-to-cell spread. Furthermore, gE is the 
primary target for VZV-specific immune responses. The vaccine efficacy against 
zoster has been determined as 97.2% overall compared with placebo [360]; in 
participants over 70 years of age, the 4-year protection vaccine efficacy against 
zoster was approximately 90% and against PHN 88.8% [359]. However, one 
negative aspect of the vaccine candidate is the increase in reactogenicity seen in 
immunised patients in response to the vaccination, though most symptoms were 
mild-to-moderate injection-site reactions probably related to the adjuvant [360]. 
These findings demonstrate that protection through subcomponent vaccine 
against an alphaherpesvirus is possible, which may provide renewed optimism 
after the recent failure of an HSV-2 vaccine based on gD [361]. Promising results 
for gG-2 as a base for HSV-2 vaccine have been described recently by our 
laboratory [362-364]. So far, this subcomponent vaccine has only been tested in 
animal models. The primary goal for HSV vaccination has been a protection 
against genital herpes, but an efficient vaccine should also provide immunity 
against CNS infections, as has been described for VZV vaccine [256, 365], and 
also for morbilli vaccine [366]. 
Antiviral treatment  
 CNS infections caused by alphaherpesviruses have, unlike many other viral 
CNS infections, a highly recommended antiviral therapy available in the form of 
the nucleoside analogue acyclovir. Acyclovir is a structural analogue of 2-
deoxyguanosine, apart from a modification in the cyclic ring where the 3’-
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positioned carbon has been removed (Figure 21) [367]. The 3’ carbon is normally 
involved in creating a phosphodiester bridge to the following nucleotide.  
 The introduction of acyclovir in HSE therapy markedly reduced the mortality 
rate from 70% to the current 10-20% [209, 212, 368]. The effectiveness and non-
toxicity of acyclovir is explained by the design of the drug. For acyclovir to be 
activated, an initial phosphorylation step is needed, which can effectively be 
performed by the viral TK (Figure 22), while host cell TK is one million times 
less capable to phosphorylate acyclovir [367]. Therefore, acyclovir is selectively 
activated in infected cells and is almost harmless to non-infected cells, providing 
a non-toxic profile. After the initial activation, the acyclovir molecule is further 
phosphorylated by cellular kinases to its active state. The activated form of 
acyclovir can then be incorporated into the viral DNA chain, where the activity of 
viral DNA polymerase is selectively inhibited and further elongation of the chain 
is blocked due to the blocking in the 3’ carbon position of the molecule.  
 Acyclovir is very effective when given intravenously, but has a low 
bioavailability when given orally [367]. However, the bioavailability is greatly 
improved when the aa valine is connected to the molecule, resulting in an L-valyl-
ester prodrug of acyclovir known as valacyclovir (Figure 21). Once inside the 
systemic circulation, valacyclovir is transformed to acyclovir via esterase, and 
therefore valacyclovir is preferred in oral therapy [367]. 
For HSE and HSV myelitis, the recommended duration of intravenous (i.v.) 
acyclovir is 14 days to 21 days while for HSM and VZV meningitis the duration 
of therapy is usually 7 days, where only more severe symptoms or extensive 
Figure 22. Activation mechanism of acyclovir. 
Figure 21. Left: Structural formulas of 2’deoxyguanosine. Middle: acyclovir. 
Right: valacyclovir. 
 
50  C HAR LOTT A ER IKSSON  
vomiting results in a recommendation of i.v. acyclovir, otherwise oral medication 
is used [132]. Treatment of primary HSM can be performed with antiviral therapy, 
although the CNS infection can often heal by itself (one exception is in 
immunocompromised patients [243]). In recurrent episodes, antiviral treatment 
can be beneficial, but the severity of the symptoms may determine if antiviral 
therapy is needed. 
In neonatal HSV infections, acyclovir is given i.v. for 21 days, and followed 
by 6 months oral treatment. Antiviral therapy improves the outcome of neonatal 
HSV infection, especially if administered early. Better antiviral response has been 
reported in HSV-1 infected neonates than for HSV-2 infected neonates [198], 
although studies have demonstrated that neonatal patients can experience 
neurological sequelae after antiviral treatment regardless of virus [234, 236].  
For VZV, few treatment studies on CNS infections are available, and the 
recommendations are often based on case studies or case reports. In myelitis, 
meningoencephalitis, encephalitis, brain infarction and ACA (especially in severe 
cases), i.v. acyclovir is recommended [132], otherwise oral valacyclovir can be 
used. Importantly, VZV is less sensitive to acyclovir than is HSV, due to inferior 
ability for VZV to phosphorylation in the first activation step of the nucleoside 
analogue, and therefore a higher dose might be needed [367].  
Drug resistance against acyclovir is unusual in immunocompetent patient 
(<1%), but is more common for immunocompromised (3.5-10%) [369-371]. 
Resistance is most commonly due to mutations in the viral TK, although clinical 
isolates with mutations in the viral DNA polymerase also have been identified 
[372, 373].  
The effects of long-term follow-up use of valacyclovir to reduce morbidity in 
HSE patients was tested in a recent study [374]. The hypothesis was that reduction 
of persistent, low-level HSV replication in CNS after the initial i.v. acyclovir 
treatment with oral administration of valacyclovir would reduce the 
neuropsychiatric sequelae and improve the outcome. However, no significant 
differences were found between the intervention group and the control group 
given placebo. Interestingly, the authors mention that as many as 44% of the 
enrolled HSE patients (regardless of treatment group) had no or only mild sequelae 
90 days after the completion of the i.v. acyclovir treatment, which in sequel studies 
are around 50%. The authors referred to limitations of the study design that may 
have contributed to these results; only patients able to self-medicate with oral 
medication were enrolled; this would exclude patients with the least favourable 
outcome according to the Mini-Mental Status Examination (MMSE).  
Furthermore, long-term treatment with valacyclovir to prevent recurrent HSM 
has also been tested, without success [242]. The reason behind this failure remains 
to be clarified.  
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Corticosteroids 
 Despite the significant reduction in mortality, acyclovir treatment for HSE 
patients has not reduced morbidity to a comparable degree. Recently, the sequelae 
seen in these patients have been attributed to an inflammatory process rather than 
the infection itself [375]. Cytokines and chemokines excreted from glial cells in 
the infected area in the HSE brain trigger an immune response that apart from 
attacking the virus also can damage the surrounding brain structures. Due to this 
inflammatory process, corticosteroid treatment has been suggested as a suitable 
complement to antiviral therapy in HSE patients to reduce the high morbidity still 
associated with the infection. This is motivated by the reduction of the 
inflammatory response and brain oedema by the steroid treatment [375]. However, 
mostly case studies and case reports have been published on the subject [376-378], 
apart from animal studies [379].  
 Therapeutic corticosteroids are synthetic analogues of steroid hormones 
produced in the adrenal cortex of the body, where synthetic glucocorticoids can 
be used to suppress inflammatory disorders as well as autoimmune disorders. 
They have potent anti-inflammatory effects but can also cause 
immunosuppression, where the function and numbers of lymphocytes are 
decreased, as well as suppressing cell-mediated immunity in the form of cytokines 
and the humoral immunity. The anti-inflammatory effects of glucocorticoids are 
mediated through suppression of the pro-inflammatory products prostaglandins 
and leukotrienes, the two main products of inflammation. Due to the many 
properties and mechanisms of glucocorticoids, long-term therapy is associated 
with many adverse events, where for example the long-term immunosuppression 
can cause an immunodeficiency. Furthermore, as glucocorticoids resemble 
human-produced hormones, therapy for more than one week leads to suppression 
of the patient’s adrenal glands due to exogenous suppression of corticosteroid 
hormones. To avoid withdrawal symptoms, it is therefore recommended to slowly 
decrease the dose for a few days in longer therapy, rather than to interrupt 
immediately.  
 An early retrospective study on the matter provided statistically evidence of 
slightly improved outcome in HSE morbidity with combination therapy of 
acyclovir and corticosteroids [380]. However, the study group was rather small 
and non-randomized and to be able to include gender and age as other influencing 
variables, the patient material needs to be extended to make accurate predictions. 
Furthermore, dosage and length of corticosteroid treatment differed between 
patients. The same research group later described predictors for a prolonged 
clinical course in HSE patients [381], where they indicated that corticosteroid 
treatment might have beneficial protective effects against prolonged HSE course.  
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In a recently presented retrospective follow-up study [377], the difference in 
clinical outcome of children with HSE receiving antiviral treatment only, or a 
combination with acyclovir and corticosteroids, was analysed. Although few 
patients were included in the study, the authors reported a reduced morbidity in 
steroid-treated patients, but the group treated with corticosteroids still had mild 
sequelae. However, the follow-up period in this study was longer for the patients 
only receiving antiviral treatment compared with the steroid-treated patients, and 
although the authors state that steroid treatment was given “early during the 
disease” for approximately 2 weeks, the exact period of time was not mentioned.  
 In 2008, the German trial of acyclovir and corticosteroids in herpes simplex 
virus encephalitis (GACHE) [382], a randomized, double-blind multicentre study, 
was initialized, where acyclovir treatment was to be combined with either 
corticosteroid therapy or placebo, to evaluate the effect on morbidity. The purpose 
of the GACHE trial was to provide important information on the safety and 
effectivity of corticosteroid treatment in HSE therapy, under more controlled 
conditions than prevalent in previously reported studies. Unfortunately, however, 
the study has been halted due to low enrolment numbers [383].  
 Despite the positive results presented in case studies, caution has been raised 
when considering corticosteroid treatment as there have been reports of 
reactivation of latent HSV after suppression of immune response (reviewed in 
[375]). This may not be surprising as the immune response is an important first 
line of defence in the combat against the virus infection. Therefore, corticosteroid 
treatment during the early phase of HSE of immunocompromised patients seems 
motivated, but the discussion has nevertheless created a resistance among some 
medical groups to administer immunosuppressive therapy even to 
immunocompetent HSE patients.  
 Treatment regimens of viral CNS infections in general do not include any 
recommendations of corticosteroid treatment, due to this lack of clinical studies. 
However, in clinical practice, high ICP generally justifies the use of corticosteroid 
treatment to reduce the oedema, as does a clinical picture of viral myelitis 
(reviewed in [132]). The general recommendation here is early treatment for a 
short period, 3-5 days, to avoid the adverse effects associated with corticosteroids.  
Future and experimental therapy in CNS infections 
Experimental treatment with the anti-secretory factor peptide 16 (AF-16), 
which corresponds to the 16 aa amino-terminal part of the endogenous protein 
anti-secretory factor (i.e. the S5A component of the proteasome), has in two 
animal studies of HSV-1 CNS infection reduced the ICP and the lateral ventricle 
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enlargement [384, 385]. Through decrement of the ICP with AF-16, all infected 
animals survived when therapy was started 4 days after infection, in contrast to 
vehicle-treated animals that showed a mortality of 80-90% after the experimental 
infection. Despite that AF-16 did not reduce viral replication or affect antigen 
distribution, the AF-treated animals did not develop neurological dysfunctions. 
The endogenous AF protein has been shown to reduce inflammatory reactions; 
this may explain why neurological dysfunctions are not seen in AF-16 treated 
animals with experimentally induced HSE. As a small peptide, AF-16 can easily 
pass the BBB to enter the brain, and it has been demonstrated that intranasal 
delivery, as used in the studies described above, further facilitates the entry of 
drugs into the CNS [386]. Therefore, AF-16 is a highly interesting option in future 
therapy of viral CNS infections, although clinical studies are needed to confirm 
the findings from the animal model.  
Two other compounds, related to each other, PG545 and muparfostat (also 
known as PI-88), that mimic the structure of GAG chains, have been shown to 
have anti-HSV activities by our lab [387-389]. While the effect of muparfostat on 
HSV cell-to-cell spread only has been demonstrated in cell culture [389], PG545 
has also been shown to have a virucidal effect on the lipid envelope of HSV 
particles and to be protective against genital HSV-2 infection in mice [388]. 
However, these compounds have not been tested in CNS models, so the efficacy 
and outcome has not been evaluated.  
One problem associated with new medical therapy directed to the CNS is the 
passage over the BBB of the molecule of interest. Such passage requires the 
substance to display certain properties, where molecular weight, lipophilicity, 
polar surface area, charge, hydrogen bonding and molecular flexibility need to be 
optimised. So developing new therapy against CNS infections is often 
cumbersome. Instead, finding new use of drugs already known to pass the BBB is 
often of interest. Furthermore, the route of administration, i.e. subcutaneous, 
intranasal, oral, i.v. or i.c. needs to be considered.  
What has been clearly demonstrated over the years is that antiviral therapy 
alone is not sufficient to significantly reduce the morbidity of the more severe 
alphaherpesvirus CNS infections, despite a prominent reduction in mortality. In 
this thesis, corticosteroid therapy has been discussed, which usually is the first 
suggestion for immunomodulation. Although only few studies have been 
published for alphaherpesvirus [390], limited trials have also been performed on 
other viral CNS pathogens, for example on influenza virus and West Nile virus, 
where immune-modulating therapy has been tested experimentally or in a small 
clinical scale [391, 392], with positive outcome. Instead of corticosteroids, 
Srivastava et al. [391] has presented an experimental model where 
immunoglobulins have been used against West Nile virus encephalitis with 
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positive results in controlling the CNS inflammation. However, as with all 
immunomodulatory therapy, cautions must be raised about possible activation of 
other pathogens.  
To conclude, the future therapies for CNS infection might be evolving toward 
brief immunosuppressive therapy combined with antivirals (when available), and 
the restrictions for drugs to passage over the BBB need to be overcome when 
administering a drug to the CNS.  
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3. Material and methods 
Detailed descriptions of material and methods used for each paper are found in 
the enclosed articles of this thesis. Stefan Lange adapted the rat HSE model from 
a model described previously by Johnson [393], using intranasal instillation of 
virus in the olfactory region. The in vitro model for infection of differentiating 
neuronal cells was developed in collaboration with Petra Bergström and Lotta 
Agholme at the Department of Clinical Chemistry. To study the binding properties 
of gC to GAGs, a model based on surface plasmon resonance (SPR) was 
developed by Marta Bally and Noomi Altgärde at Chalmers University of 
Technology. 
3.1 Viruses and cell cultures 
 In paper I, the clinical strain HSV-1 2762 was used. This strain, obtained from 
a brain biopsy of a male patient with fatal focal encephalitis [368], was previously 
shown to be highly neurovirulent in in vitro experiments [187] as well as in animal 
experiments [394]. 
In paper III, HSV-1 strain 2762 and another clinical strain, HSV-2 VF-1181 
[187], were used. HSV-2 VF-1181 is also a neurovirulent strain, obtained from a 
patient with HSM caused by HSV-2. These neurovirulent strains from clinical 
cases were used for infection of the iPSC and differentiating neuronal cultures. 
The rationale was that these viruses would induce a virulent infection in stem cells 
similar to that seen in the CNS after HSV infection, as compared to the more non-
neurovirulent cell culture-adapted laboratory strains. Green fluorescent protein 
(GFP)-labelled virus HSV-1 K26-GFP [395] was used in immunocytochemistry 
studies (paper III). K26-GFP is a strain based on HSV-1 KOS, where a GFP-tag 
has been inserted into the capsid protein VP26 to facilitate visualisation of the 
infection.  
In paper IV, the laboratory strain HSV-1 KOS [396] was used to determine 
the importance of the mucin-like region of gC. For investigation of the function 
of gC, two mutants of KOS were also used. The first mutant had a deletion of the 
gC-region of the virus (HSV-1 KOS-gCdef) due to a frame-shift mutation of 
cytosine at position 366 in the gC-genome (Ekblad, unpublished data). The second 
mutant (HSV-1 KOS-gCΔmuc) was derived from a marker transfer procedure 
where the mucin-like region of gC (aa 33-116) had been deleted; this strain is 
described in more detail in section 3.5.  
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Green monkey kidney (GMK) cells [397] were used in cell-based assays to 
assess the yield of infectious extracellular (EX) and cell-associated (CA) virus 
(paper III and IV), and to test the effect of different compounds with antiviral 
effect on HSV-1 variants (paper IV).  
In paper III, GMK-cells and human fibroblasts were used for control assays 
of viral infection. Results were compared with results from infected cell cultures 
at four different stages during differentiation to cortical neurons from human 
induced pluripotent stem cells (iPSCs). These cells were included to demonstrate 
the differences in how the viruses act in different cell cultures.  
3.2 DNA and RNA extraction and quantification 
For extraction of viral DNA (papers I-IV), cell culture, patient and animal 
material was run on a MagNA Pure LC robot using the MagNA Pure LC DNA 
Isolation Kit I (cell and patient material) or MagNA Pure LC DNA Isolation Kit 
II Tissue (Animal tissue). Prior to DNA extraction, animal tissues were 
homogenized in a MagNA Lyser instrument by using MagNA Lyser Green Beads 
and a tissue lysis buffer [398]. 
Quantification of viral DNA was performed with qPCR for HSV-1 (papers I-
IV) or HSV-2 (paper III). Highly conserved regions of HSV-1 gB and HSV-2 
gB, respectively, were targeted with a pair of primers and a virus-specific probe 
[398]. Detection and amplification of HSV-1 and HSV-2 DNA resulted in specific 
cycle threshold (Ct) values; a standard curve with known concentrations of HSV-
1 or HSV-2 in order to determine the number of respective virus DNA copies in 
each sample.  
For detection of gene expression in rat brain tissue, homogenization was 
performed in a MagNA Lyser instrument using MagNA Lyser Green Beads 
(Roche) and QIAzol lysis reagent (Qiagen AB, Sollentuna, Sweden) and RNA 
was then extracted using the RNeasy Lipid Tissue kit from Qiagen. This 
combination of extraction methods was chosen due to the lipid nature of brain 
tissue. 
RNA quantification of AQP9 and 18S (a house-keeping gene) was performed 
in a reverse transcription reaction by using the SuperScript III One-step RT-PCR 
system from Invitrogen and commercially pre-developed TaqMan Gene 
Expression Assays (Applied Biosystems) on a 7300 real-time PCR system. 18S 
was used as the housekeeping gene based on information from previous studies 
indicating that the gene is expressed constitutively in herpesvirus-infected cells 
[399]. The ΔΔCt-method (as described by Livak and Schmittgen [400]) was used 
to determine relative concentrations of AQP9 in total RNA samples.  
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3.3 The animal herpes simplex encephalitis model 
For the animal HSE model presented in paper I, male Sprague-Dawley (SD) 
rats were used. The infective dose of HSV-1 virus was instilled in the right nostril 
of the rat under deep anaesthesia. The model provided the virus with a rapid entry 
route into the brain via the olfactory bulb, and resulted in a CNS infection 
resembling the pattern seen in human HSE. Rats have previously been suggested 
to be a relevant animal model for studies of HSV CNS infection because there are 
type-specific differences of HSV-1 and HSV-2 invasion of different locations 
within the rat brain; these type-specific differences parallel what is observed in 
humans [175]. Rats were sacrificed at days 1 to 6 post-infection, when tissue 
samples were taken for DNA and RNA extraction and quantification, and selected 
brain sections were investigated by immunohistochemistry staining. Infection 
studies did not extend beyond 6 days as the rats at this time point demonstrated 
severe symptoms. Tissues and sections from the olfactory bulb and the entry zone 
of the trigeminal nerve were of particular interest to observe which route the virus 
used to enter the CNS. For AQP9 RNA quantification, sections from the olfactory 
bulb, the AC and the hippocampus were of special interest in order to detect any 
upregulation of gene expression in HSV-1 infected animals.  
 The animal model was chosen as the viral inoculation, when HSV-1 was 
instilled to the olfactory mucosa, did not inflict any damage to the skin or the 
mucosal barrier that more invasive models can do (i.e. when virus is injected i.v. 
or i.c.). Such more invasive models can recruit inflammatory cells to the area of 
damage, which in our model could have affected the extent of the viral infection 
in the skin and mucosa and also the viral spread. In addition, i.c. injections are not 
useful for study of neuronal routes used by the virus as these would provide the 
virus with an unnatural route for entry and spread. 
Immunohistochemistry was utilized to document the viral spread within the rat 
brain. Furthermore, it also functioned as a complement to viral DNA 
quantification since this method could indicate where in a specific brain section 
the virus would be found. When viral DNA is extracted from a specific tissue, the 
viral DNA quantification can indicate a DNA concentration in one area of the 
tissue section that does not correspond to the concentration in other regions of 
brain. Therefore, staining by immunohistochemistry could indicate where the 
virus was located and actually expressed antigens within the investigated section.  
3.4 Patient material 
 In papers I and II, CSF and serum samples from HSE patients were analysed 
with enzyme-linked immunosorbent assay (ELISA) kits for AQP9 concentrations 
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and presence of complement components, with ethical approval from the Regional 
Research Ethics committee in Gothenburg. 
 Due to the rarity of HSE cases, a retrospective study design was adopted to 
obtain a study group large enough to enable evaluations and predictions. The 
patients included in the group had been admitted to the Sahlgrenska University 
Hospital Östra Sjukhuset between 1995 and 2014, with CSF and serum samples 
that either had been sent to the Virology laboratory for immediate analysis or had 
been stored at the clinic for later analysis. Patients (n = 23 for paper I; n= 35 for 
paper 2) were included based on the medical records of clinical symptoms and 
diagnoses, along with detection of HSV-1 DNA in at least one CSF sample. If 
available, serial CSF samples from several occasions were included in analysis to 
obtain information about activity over time for the analysed components of 
interest. Patient information collected was age, gender, HSV-1 DNA 
concentration in each sample (both CSF and serum), time after onset of 
neurological symptoms for each sample and score on the Glasgow outcome scale 
(GOS). 
 In addition to the HSE patient group, a control group of healthy subjects was 
used for the analysis (n = 19 for paper I; n = 11 for paper II). However, due to 
the dissimilarities in age and gender between the two groups, another control 
group of so-called “patient controls” with demographic distribution closer to the 
HSE group was also included in paper II (n = 28). This group consisted of 
subjects that had sought medical care with initial suspicion of CNS infection due 
to their symptomatic profiles, though such infections were later deemed less 
likely. The healthy controls were used to set a baseline of values in the healthy 
population while the patient controls were included to distinguish differences 
between patients with proven HSV-1 CNS infection and undiagnosed patients 
with other symptoms. 
 Serum samples were included in the ELISA analyses both as positive controls 
and for determination whether increases or decreases of components of interest 
(AQP9 or complement components) only were present in the CNS or were a result 
of passive transfer from the general circulation to the CSF.  
 The ELISA method used for the analysis was of a sandwich ELISA model 
(commercially available). For the kits used in paper I and II, the capturing 
antibody is a monoclonal and the detecting antibody is a polyclonal (personal 
communication with the manufacturing companies). The commercial ELISA kits 
were chosen as they were sensitive, i.e. could identify even low concentrations of 
antigen, and specific due to the use of two separate antibodies for capture and 
detection of the antigen of interest.  
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3.5 A model for infection of cortical neurons 
differentiating from induced pluripotent stem cells  
Figure 23. Differentiation of human induced pluripotent stem cells (iPSCs) into cortical neurons. 
Infection of cells with HSV-1 or HSV-2 or mock-infection at four time points during differentiation: 
day 0, day 30, day 60 and day 90. At time points 0h, 24h and 48h post-infection four different 
procedures were performed: supernatant was removed to obtain extracellular (EX) virus in 
supernatant, cell and viruses were harvested for cell-associated (CA) virus, lysis buffer was added to 
cells to obtain a lysate, and cells were incubated with a tetrazolium compound to measure cell 
viability in a colourimetric assay. CA and EX virus was then subject to viral titration and viral DNA 
quantification to obtain viral titre (measured in plaque forming units/ml) and viral DNA (measured 
as DNA copies per ml). Supernatant was also assayed for lactate concentration, a measurement of 
the metabolic activity in the cells. Finally, the lysate was subject for extraction of genomic DNA 
(gDNA) and total RNA. The total RNA was transcribed into cDNA and gene expression was 
analysed. 
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 In paper III, a previously described cell culture model for differentiation of 
human iPSCs into cortical neurons [401, 402] was used. At four time points during 
differentiation, representative of different stages during neuronal development, 
cells were infected with HSV-1 or HSV-2. The morphological appearance of the 
cells at different stages of differentiation is shown in Figure 23.  
Infected or mock-infected cells and conditioned media from these cultures 
were analysed for viral titres and viral DNA, cellular gDNA and total RNA, gene 
expression, cell viability, cell metabolism and complement activity (Figure 23). 
This cell culture model was chosen based on its resemblance with neuronal 
development in utero, and is a relevant model for development of human neuronal 
cells. We were interested in distinguishing if the viruses would infect the cell 
culture more profoundly at any particular stage during differentiation and in 
analysing the effects of infection on cellular gene expression of differentiation 
markers. Detection of any discriminating difference between HSV-1 and HSV-2 
infectivity in these cells would be of considerable interest, particularly with our 
knowledge of the different characteristics of the infection in neonates, older 
children and adults.  
As we were unable to determine the number of cells in each well before 
infection, we decided to infect all wells with the same concentration of virus. The 
CA viral titres and viral DNA concentrations were normalized to the cellular 
genomic DNA (gDNA) extracted from the same well in order to obtain an equal 
estimate of the viral infection for each time point of interest. The concentration of 
gDNA was chosen for normalization as it is estimated to be consistent in all cells 
for most organisms and would therefore be similar for all four time points of 
interest, and also for the control cell cultures GMK cells and fibroblasts. This 
provided information to calculate viral titre and viral DNA in relation to the gDNA 
concentration, a ratio of plaque forming units (pfu)/gDNA (for viral titre) and viral 
DNA/gDNA (for viral DNA).  
3.6 Construction of an HSV-1 strain lacking the 
mucin-like region of glycoprotein C 
Using a marker transfer assay that has been described previously [113], an 
HSV-1 strain mutant deficient in the mucin-like region of gC (Δ33-116) was 
produced in paper IV (Figure 24). Here, a mutant virus that had been selected as 
deficient in the mucin-like region through multiple passaging of HSV-1 KOS in 
GMK cells in the presence of the compound muparfostat (PI-88) [113] was 
recombined with a gC-negative virus (HSV-1 KOS-gCdef, described in section 
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3.1) (Figure 25). This was done to ensure that the mucin-like region was the only 
altered part of the genome, as the multiple passaging could also have introduced 
other mutations in the viral genome. To ensure proper marker transfer, cells 
infected with the resulting mucin-like region-deficient strain (KOS-gCΔmuc) 
were immunostained for gC-positivity using the monoclonal antibodies B1C1, 
C2H12 and C4H11 directed towards different epitopes of the gC protein. The viral 
DNA was sequenced to confirm that the defined mutation was present in the 
genome.  
The gCs isolated from wild-type HSV-1 KOS and from the mucin-like region 
deficient HSV-1 KOS-gCΔmuc (Figure 24) were extracted from lysates of EX 
virus and virus-infected cells by using immunoaffinity chromatography [66].  
HSV-1 deficient in gC
  No other mutations
HSV-1 lacking mucin-like region of gC
Other mutations elsewhere in genome
Isolation of
HSV-1 gC- DNA
Isolation of gC-1 coding region
deficient in the mucin-like region
from HSV-1 mutant DNA
Co-infection in GMK-cells
TMR
COOHNH2
Region III
  276-292
Region I
 124-137
C5/P blocking domain
         (33-123)
Region II
 223-246
Region IV
 339-366
gC-1
Figure 25. Marker transfer 
assay of HSV-1 lacking the 
mucin-like region of gC into 
HSV-1 deficient in gC through 
co-infection in GMK- cells.  
 
Figure 24. Top: Wild-type gC-1 with the mucin-like region (aa 33-116). Bottom: gC-1 Δmuc with a 
deficient mucin-like region, where the aa 33-116 residues have been deleted, thereby removing 
numerous O-glycosylation sites. 
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To assess the contribution of sialic acid (SA) to GAG-independent interactions, 
HSV-1 KOS and HSV-1 KOS-gCΔmuc were treated with neuraminidase for 
desialylation. This was performed to determine whether SA could interfere with 
the binding between GAG and virus.  
The two viral strains were examined for yield of infectious virus following 
infection of GMK cells. Here, as was done for differentiating neuronal cells, 
separate analysis was performed for the amount of virus produced by infected cells 
(CA virus) and virus released into cell medium (EX virus). Cells infected with the 
two viral strains were studied with electron microscopy. 
3.7 Surface plasmon resonance experiments 
To assess the binding properties of gC to GAGs in regards to kinetics and 
equilibrium in Paper IV, surface plasmon resonance (SPR)-based interaction 
experiments were performed. For this method, a sensor chip functionalized with 
biotinylated GAGs (hyaluronic acid (HA), CS or sulphated HA) was used. GAGs 
were biotinylated at the reducing end to enable an immobilized end-on 
configuration to a streptavidin surface, which would mimic the attachment of 
GAGs to proteoglycans on the cell surface. A constant stream of running buffer 
containing isolated gC either from KOS or KOS-gCΔmuc was then added, where 
Figure 26. Surface plasmon resonance (SPR). A running buffer containing isolated gC-1 from 
either wild-type or mutated virus was allowed to run in a constant stream over a sensor chip. The 
sensor chip had previously been functionalized with biotinylated GAGs to which the isolated gC 
could bind. The binding was recognized by a detector that recorded the reflection of polarized light 
directed towards the base of the chip.  
= gC-1
= biotinylated
   GAG
Running buffer
Sensor chip
Prism
Detector
Reflected lightPolarized light
Output
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the isolated gC could bind to the biotinylated GAGs and the binding was detected 
(Figure 26).  
For inhibition experiments, the gC1-specific monoclonal antibody B1C1, in 
which the binding site overlaps that of the HS-binding region of gC, as shown in 
Figure 5, was mixed with isolated gC and then injected over the functionalized 
sensor chip.  
To estimate the contribution of electrostatic interactions in binding of gC-1 to 
the GAG, different ionic strengths were used for the gC-1 containing running 
buffers. In addition, to obtain binding affinity of gC, a low flow of running buffer 
was used until equilibrium; this was repeated with increasing concentrations of 
gC. 
3.8 Effect of antiviral compounds on HSV-1 
infection 
Cells were infected with HSV to determine the effect of antiviral compounds 
in a viral plaque number reduction assay (paper IV). This was performed using 
either heparin or muparfostat, two compounds with antiviral effect. Muparfostat 
is an oversulfated oligosaccharide that mimics GAGs; heparin is a GAG closely 
related to HS. Working dilutions of KOS or KOS-gCΔmuc virus were added serial 
five-fold dilutions of the compounds; these mixes were held at room temperature 
for 10 min. GMK cells were infected with the virus-compound mixes, and cell 
culture plates were incubated for 3 days. The number of plaques formed in the 
plates inoculated with each compound premixed with virus was counted. From 
this, the 50% inhibitory concentration (IC50) was calculated.  
Neuraminidase-treated viruses were also tested for their sensitivity to heparin 
to establish the effect of GAG interactions after this modification, following the 
procedures described above.  
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4. Results and discussion 
 Appropriate cell and animal models for studying alphaherpesvirus infections 
in the CNS are scarce and can seldom mimic the entire course of the disease. The 
role of the viral glycoproteins during cell entry and egress has been studied 
previously, but the role of the so-called mucin-like regions of some glycoproteins 
is not well characterized. Furthermore, little is known of the role the immune 
responses have in the damage seen in in the brain after infection, but more and 
more evidence seems to indicate that the virus alone is not the cause of the 
symptoms and sequelae related to alphaherpesvirus CNS infections (reviewed in 
[403]). In this thesis, viral spread within the CNS, viral adhesion and release, the 
sensitivity to HSV-1 and HSV-2 infections of developing neuronal cells and the 
activity of the innate immune response were investigated.  
4.1 A pathway for contralateral spread of HSV-1 
We used a rat model to provide information on routes of transport for HSV-1 
spread in HSE (Paper I). Here, we found that after intranasal instillation in the 
right nostril only, virus distribution, as detected in the form of HSV-1 DNA, was 
observed early both in the right trigeminal ganglion and lamina cribrosa (Paper I: 
Fig. 1). The latter region is a sieve-like structure of the ethmoid bone, between the 
nasal cavity and the brain, through which the olfactory nerves pass. Viral spread 
to the parallel structures on the left side of the brain was delayed by 2 to 3 days. 
Antigen detection by immunohistochemistry supports the findings of a delayed 
spread to the contralateral hemisphere (Paper I: Fig. 2-3). Contralateral viral 
spread may be limited by an anticipated transport of virus across synapses. This 
was further illustrated by findings in the olfactory bulb, which was initially 
reached from the olfactory mucosa through passage of synapses (as illustrated in 
Paper I Fig. 10a). In the right olfactory bulb, HSV-1 DNA was not found until 
rather late after infection but surprisingly, HSV-1 DNA in the left olfactory bulb 
was found near the time of its detection in the right bulb. One explanation to this 
finding was provided by immunohistochemistry where HSV-1 antigen was 
detected in the anterior commissure (AC). This is a bundle of nerve fibres for 
contralateral communication found in an evolutionary conserved part of the brain. 
The AC provided the virus with a shortcut for rapid spread to the left olfactory 
bulb and to the limbic system (Paper I: Fig. 4). The suggested spread of virus in 
rat brain after infection with HSV-1 in the olfactory mucosa is illustrated in Figure 
27.  
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Immunohistochemistry demonstrated that infected cells in the AC 
morphologically resembled oligodendrocytes. In addition, these cells were not 
positive for markers specific for neurons, astrocytes or microglia (Paper I: Fig. 5). 
This finding may be important for explanation of the rapid contralateral spread of 
the virus. Given the difference in time for the virus to reach the right olfactory 
bulb compared with the right trigeminal ganglion, synapse passage may be a time-
limiting step in the spread of HSV-1.  
Initially, we did not have a suitable immunohistochemistry marker for 
oligodendrocytes. To identify oligodendrocytes as the cells targeted by HSV-1 in 
the AC, morphological resemblance combined with no apparent co-staining of 
other glial cells was used. However, later we discovered that a polyclonal antibody 
for AQP9 co-stained with the presumed oligodendrocytes in the AC (Figure 27). 
Figure 27. Left: routes for HSV-1 entry and spread in rat brain. Dashed arrows indicates suggested 
routes for spread. Right: Staining for AQP9 in the anterior commissure (AC). Top right: Combined 
staining for AQP9, HSV-1 and nuclei. Second top right: Staining for nuclei with DAPI (blue). 
Second bottom right: Staining for AQP9 with a rabbit polyclonal antibody (red). Bottom right: 
Staining for HSV-1 with a mouse monoclonal antibody (green).  
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In addition, immunohistochemical observations showed enhanced staining for 
AQP9 in HSV-1 infected animals as compared with uninfected controls, 
indicating that AQP9 expression may be increased in these animals (data not 
shown). 
Unlike corpus callosum, the main route for communication between the two 
brain hemispheres in placental animals but not in other vertebrates, the AC 
commissure is present throughout the animal kingdom. However, due to the 
existence of corpus callosum, the AC in placental animals is less extensively 
developed compared with for example in marsupials [404, 405]. This knowledge 
encouraged us to suggest that the use of the AC for spread could indicate that 
HSV, and maybe all alphaherpesviruses, targeted this route in the brain since long 
in evolution.  
Although it has been previously demonstrated that HSV-1 can enter the brain 
via both the trigeminal nerve and the olfactory bulb [214, 217, 218, 406], the 
further spread to the limbic system, where much of the cell damage of the infection 
is localised [407], is less well known. When evaluating whether the results from 
our rat model reflect the actual viral spread in HSE patients, the autopsy findings 
by Esiri [214], where HSV-1 antigen was found both in the trigeminal ganglion 
and the olfactory bulb in HSE-patients deceased early in infection, should be 
considered. This indicates that the route of infection seen in the rat model is similar 
to that found in humans. Esiri also found evidence of HSV-1 antigen being 
expressed in the AC of some subjects, again of relevance for our findings in the 
rat model.  
Cultured oligodendrocytes have previously been tested for their susceptibility 
to HSV-1 and were judged to be highly sensitive as compared to other cells of 
different origins [96, 161, 408]. However, HSV-1 infection of oligodendrocytes 
has rarely been described in clinical reports. This is in contrast to observations 
made in astrocytes and neurons [214, 409]. Our findings suggest that the myelin 
sheath produced by oligodendrocytes may provide the virus with the opportunity 
to avoid a possible delay associated with viral transport over synapses. 
Next, due to the noted increased presence of AQP9 in infected animals, we 
were interested in investigating the gene expression of AQP9 in rat brain tissue. 
Here however, no increase in AQP9 gene expression was seen in infected rats 
compared with control rats, but rather, the gene seemed to be constitutively 
expressed during infection (Paper I: Fig. 9).  
Our next step was to investigate AQP9 concentrations in samples of CSF and 
serum from HSE patients, to relate the increased presence of AQP9 antigen 
detected in the animal model to a clinical setting. CNS aquaporins, including 
AQP9, have been implicated in the development of brain oedema during trauma 
as well as during infection with other pathogens [410, 411]. As brain oedema is a 
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common finding in HSE patients, which often can contribute to the neurological 
pathology if left untreated [211], we were interested in investigating if AQP9 
antigen concentrations differed between HSE patients and healthy controls. We 
also analysed concentrations of the other two CNS aquaporins, AQP1 and AQP4, 
in the CSF and serum samples by ELISA assays. In contrast to our findings on 
gene expression, AQP9 concentrations were significantly increased in CSF from 
HSE patients as compared with healthy controls (Figure 28). Notably, AQP9 
concentrations were below the minimum for detectable concentration in CSF from 
all healthy controls. The increase in AQP9 concentrations was seen in early HSE, 
but not in later stages when HSV-1 DNA was undetectable. No significant 
differences in protein concentrations in CSF were revealed either for AQP1 or for 
AQP4 between HSE patients and healthy controls (Figure 28).  
Although AQP9 is one of the three aquaporins expressed in the CNS, this ion 
channel protein has not been extensively investigated in patients or in animal 
models. This is in contrast to AQP1 and, in particular, to AQP4. In a previous 
animal study, the gene expression of these two CNS aquaporins was studied in 
HSV-1 infected mice. Interestingly, the results demonstrated that AQP4 
expression was downregulated during acute HSV-1 infection [333] and increased 
in late infection, while the opposite pattern was demonstrated for AQP1. This may 
suggest that if we had examined the gene expression in the brain rather than the 
protein concentrations in CSF for these two aquaporins, our results could have 
been different. 
The increased AQP9 levels we observed in HSE patients have previously been 
noted in animal models utilized to investigate other brain trauma (reviewed in 
[412]). One explanation proposed for the increased aquaporin concentrations 
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Figure 28. Aquaporin concentrations in samples of CSF from control subjects (n= 15) and herpes 
simplex encephalitis (HSE) patients (n = 19). Left: AQP1 concentration in CSF. Middle: AQP4 
concentration in CSF. Right: AQP9 concentration in CSF. ns = non-significant, ****= p<0.0001. 
The Mann-Whitney U test was used to obtain p-values. 
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presented here, and also for findings recorded in patients with other brain trauma, 
is that this elevation constitutes a functional response to brain oedema in order to 
reduce the increased ICP. On the other hand, AQP9 has also been reported to be 
expressed in leukocytes [413] and, as HSE normally leads to an increase in CSF 
and brain leukocytes, the observed increase in AQP9 noted here could be 
explained by a cellular inflammatory response in this disease. 
4.2 The complement system is activated both in 
acute and late herpes simplex encephalitis 
 The persistent neurological sequelae seen in HSE patients have previously 
been suggested to be caused by the immune response rather than by the infection 
itself. In Paper II, we examined the activity of the complement system, a part of 
the innate immune response, both in acute and long-term HSE to investigate if the 
activity can be related to neurological complications. One reason for this 
investigation was the reports from cell culture and animal studies of a direct 
binding interaction between C3b and gC on HSV-1, where gC-1 functions as a 
receptor for C3b [414]. Since these discoveries were made in the end of the 1980s 
and beginning of the 1990s, several cell culture experiments have been performed 
with the aim of elucidating the gC-C3b bindings at the molecular level, but studies 
of the clinical importance of this interaction during HSE are lacking.  
 For our study, we tested seven different complement components (C1q, 
CFB, C3a, C3b, C4b2a, C5 and C5a), representative of the three different 
activation pathways of the complement system as well as of the terminal pathway 
(Figure 17). Results for HSE patients were compared with those for patient 
controls and healthy controls, where the healthy controls were utilized for baseline 
concentrations and patient controls were used to identify any differences or 
similarities between HSE patients and undiagnosed but symptomatic subjects 
(Paper II: Fig. 1). Here, we observed that concentrations for C1q and CFB were 
similar in CSF for all three studied groups. Although C4b2a concentrations were 
significantly lower in HSE patients compared with patient controls, only a few 
patients contributed to this difference. Therefore, these results received less 
attention, especially as there was no difference seen between healthy controls and 
HSE patients. C3a, C3b, C5 and C5a concentrations on the other hand were 
significantly higher for HSE patients as compared with healthy controls. A 
significant increase in C3a and C5a was also detected in HSE patients as compared 
with patient controls. In addition, we found that the concentrations of C3a, C5, 
and C5a were not significantly increased in serum from HSE patients as compared 
with healthy controls (no data was available for C3b levels in serum from healthy 
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controls). These findings indicated that the complement components were 
produced intrathecally rather than being recruited from the general circulation. 
Intrathecal complement production during CNS infection has also been reported 
by others [283, 415]. 
The anaphylatoxins C3a and C5a can, among other functions, recruit the 
adaptive immune response to the site of damage and thus have a pro-inflammatory 
effect. We were therefore interested in analysing the differences in complement 
activity during acute and prolonged HSE. Here, we found that C3a concentrations 
tend to increase over time, while C5a levels slightly decreased during follow-up 
(Paper II: Fig. 4). Nevertheless, the two anaphylatoxins were significantly 
increased as compared with both control groups in early as well as in late HSE 
(Paper II: Fig. 2).  
Then, we analysed our results in regards to GOS-reported outcome scores for 
HSE patients, where no differences in complement concentration were found in 
the initial sample in relation to outcome (Paper II: Fig. 5). This was unexpected, 
as our hypothesis was that either increased, or reduced, complement activity could 
affect the extent of neurological damage in the HSE patients, as was previously 
reported in bacterial meningitis of different origin [284]. However, a separation 
of the HSE patients into five groups of GOS score gave low numbers of cases in 
each group, making interpretation of the results difficult. Furthermore, 
complement measurement in late HSE could be biased as patients with GOS score 
1 had a shorter follow up since they only could be sampled until they deceased, 
which we could not correct for in our analysis.  
In paper I, AQP9 was found to be increased in CSF of HSE patients and was 
suggested to contribute to ICP. The increased activity of the complement 
components in Paper II could therefore be a response to leaking cells, and brain 
oedema, as well as to other damage caused by the virus. 
During the work with Paper II, we also studied CSF and serum material from 
patients with other viral CNS infections for comparison, although these data have 
not yet been published. Amongst the CNS infections, this material included 
patients with TBE. While almost all HSE patients had follow-up samples, only a 
few TBE patients had samples collected over time. Here, we found that CSF 
concentrations of C3a were significantly increased in HSE patients as compared 
with TBE patients (Figure 29), while C5a and C3b concentrations were similar 
between HSE patients and TBE patients. Interestingly, C1q levels were 
significantly higher in TBE patients as compared with HSE patients (Figure 29). 
This finding was particularly intriguing as C1q did not differ significantly for HSE 
patients as compared with either of the two control groups (Paper II: Fig. 1), 
indicating that in TBE virus infection, the classical pathway of the complement 
system might be preferentially activated in the CNS.  
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Neurological sequelae, which are commonly diagnosed in HSE patients, have 
also been reported in 30-50% of TBE patients in long-term follow-up [416-419]. 
Unlike the HSE patient material, where serial samples were obtained for up until 
two years after onset of symptoms, the TBE material we had access to was mainly 
sampled within the first 20 days after onset of symptoms. Therefore, any 
predictions of long-term complement activity, and eventual relation to outcome 
for TBE patients, are difficult to make. However, the increased concentrations of 
C3a for HSE patients as compared with TBE patients could be related to the 
increased levels of neuronal and astroglial cell damage markers reported in a 
previous study [350].  
Interestingly, C1q, which was found to be increased in TBE patients, has been 
reported to interact with the non-structural glycoprotein 1 (NS1) on the surface of 
Dengue virus, another flavivirus related to TBE virus [420]. This could indicate 
that the increased concentrations of C1q in TBE patients actually reflect the 
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Figure 29. Concentration of complement components in CSF samples from TBE (n= 39) and HSE 
patients (n= 37). Top left: C1q concentration in CSF. Top right: C3a concentration in CSF. Bottom 
left: C3b concentration in CSF. Bottom right: C5a concentration in CSF. ****= p<0.0001, ns = non-
significant. The Mann-Whitney U test was used to obtain p-values. 
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differences in complement activation pathways as suggested above. If so, 
flavivirus glycoproteins may bind C1q, in a manner similar to the function of 
HSV-1 gC as a receptor for C3b. NS1 of different flaviviruses (including West 
Nile virus and Zika virus) have recently been demonstrated to be directly involved 
in the interactions of the MAC [421]. These findings indicate that as many viruses 
function as receptors for complement components, the importance of the 
complement system in response to a viral infection may previously have been 
underestimated.  
  Our findings of complement activity both in acute and prolonged phases of 
HSE could indicate that immunosuppressive therapy may be beneficial in HSE 
patients in combination with antiviral treatment, as has been suggested in different 
case reports. Despite of the negative effects of corticosteroid therapy, where the 
CNS infection by alphaherpesviruses can be triggered by the immunosuppression 
(reviewed in [375]), or of reports where corticosteroid treatment has not had the 
desired effect [381, 422], the benefits on the outcome of corticosteroid treatment, 
initiated after PCR confirmation of HSE, appears to be promising. If the immune 
activity in CNS could be reduced for as long as HSV-1 DNA can be detected in 
CSF, the cortical damage could possibly be diminished, even if not completely 
abrogated. However, to find the appropriate dose for and duration of 
immunomodulating therapy, clinical trials like the GACHE study initiative [382] 
will be needed.  
4.3 Differentiating neuronal cells vary in their 
vulnerability to HSV-1 and HSV-2 infection  
 To reduce the need for animal models of HSE, we tried to identify a new cell 
culture model to study HSV-infection. In Paper III, HSV infection of cortical 
neurons differentiating from iPSCs was described. This model may imitate 
neuronal differentiation under the gestation period, where proliferation of cells is 
high in early differentiation, while the cells have reached a post-mitotic phase in 
later stages of differentiation (Paper III: Figure 1).  
We infected cells at four representative stages of differentiation, with CNS-
derived isolates of HSV-1 or HSV-2. Between the four differentiation stages, we 
found differences in cell viability and virus production after infection with these 
viruses (Paper III: Figure 2-4). The main finding held for both viruses was that the 
cytopathogenic effect was most pronounced in cells infected on day 30 after onset 
of differentiation, although virus yields reached a maximum in cells infected on 
day 90 of differentiation. Many different processes occur during cell division that 
may contribute to these findings. Possibly, proliferating cells, commonly observed 
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during early differentiation (and present in cultures of human fibroblasts and 
GMK-cells) are more vulnerable to HSV-infection than post-mitotic cells seen in 
late differentiation and may contribute to the cytopathogenic effect on day 30. One 
factor that argues for this hypothesis is the latent infection that HSV can establish 
in mature neurons through expression of genes that suppress autophagy in these 
cells (reviewed in [334]), where the virus is protected and maintained in a 
persistent state. On the other hand, undifferentiated iPSCs did not show high 
production of infectious virus, nor was their cell viability affected, despite their 
high frequency of mitosis. Therefore, other factors apart from proliferation, for 
example a changing pattern of expression of viral surface receptors during 
differentiation, could also contribute to the varying susceptibility to viral 
infection. Another possibility is a beneficial effect of synapse formation on viral 
replication and cell viability. In late infection, the neurons are connected via 
synapses, which facilitate the transmission of virus to other cells, while these 
connections are lacking in early infection. One suggestion here is that without 
synapses, the egress of progeny virus is hampered, which would increase the 
pressure of the neuron/neuronal progenitor cell in the direction of 
cytopathogenicity 
 The aim of Paper III was to characterize eventual differences between 
HSV-1 and HSV-2 in a novel cell culture model of CNS infection, to elucidate the 
neuropathogenicity of the two viruses during specific stages of neuronal 
development. We observed reduction in cell viability in early differentiation for 
both HSV-1 and HSV-2, as compared with uninfected control cells (Paper III: 
Figure 4). This reduction was greater for HSV-2 infected cells despite similar titre 
after 48h (Paper III: Figure 2, 3). Our results do not explain why neonates are more 
severely harmed by HSV-2 infection than by HSV-1 infection, but do indicate that 
our cell model is useful for studying HSV infection in the developing brain. 
 As was seen in Paper I, the importance of the sensitivity of additional brain 
cells, not just neurons, to infection with HSV must be considered [423-425]. Our 
cell cultures contained mainly neurons (at least 95%), with appearance of only a 
few astrocytes in late stages of differentiation. In addition, by electron microscopy 
we have observed a cellular structure that we interpret as being an oligodendrocyte 
(Figure 30). These three cell types, neurons, astrocytes, and oligodendrocytes, 
develop from the neuroectoderm. Microglial cells, on the other hand, are not 
expected to be found in the differentiated iPSCs cultures as they originate from 
another embryonic layer. Therefore, to get a better understanding of the behaviour 
of HSV-infection in differentiating neuronal cells, and thereby in developing 
brains, cell cultures with both neurons and all glial cells are needed.  
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Figure 30. Electron microscopy of cortical neurons (day 90 of differentiation) infected with GFP-
tagged HSV-1. Top right: Overview. Boxes labelled A to D indicate enlarged sections. (A) HSV-1 
virion in exocytic vesicle at the peripheral part of cytoplasm. Note presence of a single virion in this 
vesicle and of several virion-like enveloped structures lacking typical viral capsid in another exocytic 
vesicle. (B) Presence of virion-like enveloped structures in exocytic vesicles. Note absence of typical 
viral capsids inside these structures and presence of tubulo-vesicular (elongated vesicles) forms of 
these exocytic vesicles. (C) Oligodendrocyte-like cell attaching to cortical neuron. Note presence of 
rough endoplasmic reticulum structure in cortical neuron just below the cell plasma membrane 
fragment contacting the oligodendrocyte outer membrane. (D) Inside the nucleus there are >10 
capsids of which two are empty (no DNA inside). In the perinuclear space, on the right side of the 
nucleus, there are a substantial number of empty capsids and some complete viral particles.  
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As we found in Paper II, the immune system is activated during HSV CNS 
infection. Besides the complement system, increments of other signalling proteins 
that can stimulate the adaptive immune response have also been described. To 
assess the potential complement reactivity of the HSV infected iPSC system, the 
cells were examined in the ELISA complement assays as outlined in Paper II. 
However, no significant differences were detected between infected cells and their 
controls (Paper III: Figure 5). Despite reports of production of different 
complement components in different cells of the CNS, a full response of this 
system requires the presence of all types of CNS cells. Furthermore, to inflict the 
damage to cortical neurons that is found in the brains of HSE patients, presence 
of an immune response might be needed, which could explain why the cell 
viability was almost unaffected by infection in late differentiation.  
Our study shows that cortical neurons can be infected with a low dose of HSV, 
and can replicate the virus efficiently. Therefore, this model does resemble the 
infection in HSE patients where initial virus input to the brain is probably very 
low, but increases through replication. The absence of effect on cell viability after 
infection in cell culture of mature cortical neurons may again indicate that other 
cells than neurons need to be present to provide for cytopathogenic virus 
replication, as the neurons were devoid of complement activation and were less 
vulnerable to infection at this stage of differentiation. 
Given the fact that HSV-2 infection in adults is associated with meningitis, 
while HSV-1 is associated with the more severe HSE, several factors must 
influence the virus preferences for site of infection, including glycosylation 
patterns on the host cell surface, which will be discussed in the next section. Why 
HSV-2 affects neonates more severely than adults is unclear and proper 
explanations are difficult to give. Furthermore, why HSV-2 after the neonatal 
period infects the meninges rather than the actual cerebrum, as HSV-1 does, is 
unclear, but could depend on the intrinsic, type-specific, properties of the two 
viruses during their replicative cycle.  
4.4 The mucin-like region of glycoprotein C 
contributes to virus binding/entry and release of 
progeny virions from cell surface 
HSV-1 and HSV-2 differ in their interactions with the cell surface attachment 
receptors known as GAGs [66]. These differences in virus-cell interactions are of 
potential importance for viral tropism and pathogenesis. To define the role of the 
mucin-like region of gC in attachment to and release from GAGs on the cell 
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membranes during viral entry and egress, the influence of the highly O-
glycosylated mucin-like region on GAG-binding properties was studied in Paper 
IV. For this purpose, we utilized a previously defined mutant virus of HSV-1 KOS 
that lacked the mucin-like region (i.e. aa 33-116) after selection during repeated 
passages with the heparin analogue muparfostat (PI-88) and compared its GAG-
binding properties with that of the parental strain [113].  
Firstly, the reactivity with three gC-targeting antibodies (B1C1, C2H12 and 
C4H11) was tested for both the mutant and the wild-type virus, to establish that 
deletion of the mucin-like region had not extensively modified the conformation 
of the gC protein. The ELISA results showed no major alterations in reactivity and 
hence in conformation between the mutant and the wild-type virus. The specific 
viral infectivity was then calculated by dividing the number of viral DNA 
copies/ml (which reflects the total number of viral particles) by the infectious titre 
(pfu/ml; reflects the total number of infectious viral particles) in preparations of 
purified virus. Here it was found that the deletion of the mucin-like region affected 
the virus moderately, requiring around twice the amount of viral particles per 
infectious unit compared with the parental virus, i.e. one out of seventeen mutant 
virions and one out of ten wild-type virions were infectious. Altogether, these 
results indicated that while the conformation of gC is not greatly altered by a 
mutation in the mucin-like region, as compared with its wild-type strain, the 
mutation somehow affected the infectivity of the virus, indicating the importance 
of the mucin-like region in HSV-1 infectivity. 
Using a cell culture assay, we then tested the effect of two compounds with 
antiviral properties (GAG-mimetic muparfostat and heparin), that function as 
inhibitors of virus-GAG interactions (Paper IV: Fig. 2). Here we found that the 
mutant virus required almost three times higher concentrations of the compounds, 
as compared with the wild-type virus, to reach the IC50. In addition, even at the 
highest tested concentrations of the compounds, the infectivity of the mutant virus 
was less inhibited than that of wild-type HSV-1. The interference on the GAG-
binding interactions of the virus by SA, which is a terminal sugar residue found 
on different viral glycoproteins including gC-1 and its mucin domain, was tested 
by treating the virus with neuraminidase. This enzymatic cleavage resulted in 
slightly reduced sensitivity to heparin (IC50 of approximately 1 µg/mL) for the 
wild-type virus devoid of sialic acid as compared to untreated virus (IC50 of 
approximately 0.5 µg/mL). In contrast, an increased sensitivity to heparin (but 
only at low concentrations) was observed after neuraminidase treatment of the 
mutant virus. Together, these results confirmed the importance of the mucin-like 
region of gC for modulation of its GAG-binding activities during viral attachment. 
Furthermore, mutations in the mucin-like region can alter the binding of gC to 
GAG-based inhibitors.  
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Next, the yield of newly produced infectious mutant and wild-type viruses was 
tested in cell cultures to determine the amount of infectious virus retained by the 
cell (cell-associated (CA) virus), and the amount of virus released from cells into 
culture medium (extracellular (EX) virus) (Paper IV: Fig. 3). Here, we found that 
the amount of CA virus produced by the mutant virus was approximately 2-5 times 
less than that of the wild-type virus, while the amount of EX virus was reduced by 
approximately 20-600 times for the mutant, depending on the time after infection 
when the comparison was made. These significant differences, especially in viral 
egress, could suggest that newly produced virions of the mutant virus, devoid of 
the mucin-like region, were trapped by GAG chains present on the surface of 
infected cells. To verify this assumption, cells infected with mutant virus or wild-
type virus were examined by electron microscopy. Viral particles were found to 
be present on the surface of infected cells for both viruses, but for the mutant virus 
approximately two times more viral particles were retained on the cell surface 
(Paper IV: Fig. 4). Altogether, these data strongly supported the importance of the 
mucin-like region of gC both in attachment of HSV-1 to cells and in release of 
newly produced virions from the surface of infected cells.  
To study the interactions between gC and GAGs on a glycoprotein level, 
particularly in relation to the mucin-like region, binding studies were performed 
using a surface-based assay. Here, using an SPR-based platform with GAGs 
biotinylated at the reducing end attached to the sensor surface (Paper IV: Fig. 1), 
the binding of gC molecules purified from the mutant and wild-type viruses to the 
GAGs was investigated. We found that both the mucin-like region-deleted mutant 
gC and the wild-type gC bound to sulphated GAGs (CS and sulphated HA), which 
indicated that the presence of the mucin-like region was not required for binding 
to GAGs per se (Paper IV: Fig. 5). This is not surprising, as the GAG-binding 
region of gC is situated downstream of the mucin-like region. In addition, neither 
the mutant nor the wild-type gC bound well to non-sulphated GAGs, confirming 
that the interaction between gC and GAG requires the presence of sulphated 
groups on the GAG molecule. 
Using B1C1, a monoclonal antibody recognizing a region partly overlapping 
the HS and CS binding site on gC [117], a competitive assay was performed to 
study the nature of the gC-GAG interaction. When the glycoprotein was mixed 
with the antibody prior to the SPR-based experiments, B1C1 effectively reduced 
binding to sulphated GAGs for both the mutant and the wild-type gC. This 
confirmed that also in the present model, the interactions between gC and GAGs 
involved the previously mapped GAG-binding site (Paper IV: Fig. 6). 
Furthermore, we tested the contribution of electrostatic interactions for binding of 
gC to GAGs. For this, a hypertonic running buffer was used, where binding levels 
of the glycoprotein at saturation were compared with that of runs performed with 
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isotonic buffer. It was found that binding to CS was reduced almost equally for 
the mutant and the wild-type gC, while for sulphated HA, the reduction in binding 
was greater for the wild-type virus than for the mutant. These results indicated an 
important role for electrostatic interactions in binding of gC to GAGs, at least 
under the conditions of this experiment, while the deletion of the mucin-like 
region may decrease the sensitivity for gC to a hypertonic solution in binding to 
some GAGs. Also, treatment of virus with neuraminidase lead to decreased 
binding of the mutant gC to CS, while the binding of the wild-type gC increased 
(Paper IV: Fig. 6). In the cell-based experiments with viral particles, the 
desialylated virions were less dependent on the GAG-specific interactions for 
attachment and rather used other virus-cell interactions. This could not be 
observed in the SPR-based experiments with gC due to the lack of other receptor 
molecules than GAGs in that system. 
Next, the binding affinities between gC and GAGs were determined for both 
the mutant and the wild-type gC (Paper IV: Fig. 7). Here, it was found that the 
mutant gC had a weak cooperative behaviour, but no such property was found for 
wild-type gC. This indicated that binding of one mutant gC molecule to a GAG 
chain will facilitate the binding of the next gC. More importantly, the affinity of 
mutant gC to sulphated GAGs was found to be lower than for wild-type gC. 
However, testing the dissociation of gC from sulphated GAGs, the complex 
between mutant gC and GAG, in contrast to the wild-type gC-GAG, was not found 
to dissociate under the conditions of the experiment (Paper IV: Fig. 8). Therefore, 
these results again confirmed what was observed in cell-culture experiments, that 
the mutant gC was less likely to bind to GAGs with the specificity observed for 
the wild-type gC. However, once the complex between gC and GAG is formed, 
the mutant gC-GAG complex is more stable, which agreed with the observations 
by electron microscopy showing enhanced trapping of mutant virus particles on 
the surface of infected cells (Paper IV, Fig. 4).  
As SPR-based experiments only could be used to study the interactions on a 
glycoprotein lever, total internal reflection fluorescence (TIRF) microscopy was 
used to study the binding of the whole virus particle to GAGs (Paper IV: Fig. 9). 
In line with the data obtained using purified gC molecules, the association of the 
mutant virus particles to sulphated GAGs was found to be decreased as compared 
with the wild-type virus particles.  
Overall, the findings in Paper IV demonstrated that the mucin-like region is 
important for the gC-GAG interactions both during attachment of virus to cell and 
during release of newly produced virions from the surface of infected cells. While 
virus with a deletion of the mucin-like region of gC can still bind to cells, the 
infectivity and the spread of virus is not as efficient. This could suggest that the 
modulatory interactions between cell surface GAGs and the mucin-like region of 
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gC may induce a conformational change in the GAG-binding site of gC to promote 
a well-balanced gC-GAG interaction of importance for specific HSV-1 attachment 
to cells and release of progeny virions from cell surface. However, other 
explanations such as steric hindrance and/or slight repulsion offered by the mucin 
region might contribute to the efficiency of full gC in GAG binding. 
 The experimental model in Paper IV did not include HS, the GAG that 
probably is the most important receptor in HSV-1 attachment to cells. However, 
it has been shown in previous studies that HS and CS bind to approximately the 
same region of gC [63] and that in the absence of HS, HSV-1 can utilize CS for 
attachment instead [62, 63]. Furthermore, the kinetic properties of gC have been 
assessed in a previous study [127], where a mucin-deleted virus with a larger 
deletion than our virus mutant was used. In this study, it was found that the mutant 
gC had lower affinity for HS as compared with the wild-type gC, while the 
complex between HS and mutant gC was less likely to dissociate than that with 
the wild-type gC. Both observations were in line with our findings. However, 
while we used full-length gC, where the transmembrane region was intact to 
preserve the native conformation of the protein, the other study used gC without 
the transmembrane region. This, in addition to the different GAGs used in the 
experiments, could explain some of the differences in affinity noted between the 
two studies. Recently, the mobility of HSV-1 particles on immobilized GAGs has 
been described [426], where it was demonstrated that both the degree of and 
pattern of sulphation on GAGs were associated with the movement of virus along 
the surface. This was hypothesised to resemble the in vivo movement during 
cellular infections, allowing the attached viral particles to search for the next 
receptor of the entry cascade. It was found that both HS and CS efficiently 
promoted lateral movement of HSV-1 particles in comparison to an artificially 
sulphated GAG in form of over-sulphated HA that rendered viral immobility after 
binding. Hence, we suggest that the burst-like pattern of sulphated stretches on 
natural cell surface GAGs such as CS and HS is more important for mobility than 
the actual degree of sulphation. 
The reason for using KOS, a laboratory strain, for preparation of the mutant 
virus was that the more neurovirulent virus 2762 did not produce a mutant 
deficient in the mucin-like region after repeated passages with muparfostat. 
However, the mutant virus used in this study will be tested in the animal model 
presented in Paper I. Despite the lower neurovirulence of the KOS strain, it would 
be of interest to investigate whether and how the differences in GAG interaction 
found both for mutant gC and mutant whole virions in vitro, would modulate the 
viral experimental infection in the more complex in vivo conditions in the presence 
of immune responses and several other binding molecules. The increased 
complement activity in the acute infection of HSE patients, as described in Paper 
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II, will probably also be present in the animal model, and therefore it might be 
difficult to distinguish the GAG-related activities from other functions of the 
mucin-like region of gC-1 in vivo. Complement component C3b can use gC-1 as 
a receptor and the mucin-like region can sterically hinder binding of properdin and 
C5 to C3b [287]. Therefore, in an in vivo condition, the mutant virus may appear 
to be more susceptible to complement degradation. The GAG-binding and C3b-
binding regions of gC-1 overlap, as has been demonstrated by the mab B1C1 that 
blocks binding of both GAGs and C3b to gC [125]. 
In the differentiating neuronal cell model (Paper III), we found no extensive 
complement activity in the cell cultures. This suggests that the differentiating cells 
can be infected with HSV-1 where the mucin-like region of gC has been deleted, 
without any impact from this immune activity. In the absence of complement 
activity such as in the differentiating neuronal cell culture model, infection of cells 
with this mutant virus may help to elucidate the susceptibility to HSV-1 of neurons 
at different stages of differentiation and the role of GAGs in this process.  
For HSV-1, the similarities in gC binding to complement components on one 
hand and GAGs on the other hand, as has been in focus of this thesis, may not be 
of utmost interest. Rather, the subtle differences between these interactions may 
be of interest in the future, where numerous questions are yet unanswered. Why 
does the virus use the same glycoprotein for blocking complement activity and for 
attachment to cells? Binding of C3b to gC-1 may impair the attachment to cells, 
as the GAG-binding region overlaps with the C3b-binding region. Can the 
complement components enter the cell upon infection along with the virus? For 
non-enveloped viruses, it was recently demonstrated that C3 can be carried into 
the cell through covalent attachment to the virus [427]. Is there an unknown effect 
of complement components intracellularly? For the intracellular C3-transfer with 
virus, cell autonomous immunity was activated [427]. This could possibly indicate 
that if complement components are transferred intracellularly with HSV-1 in 
neurons, both autophagy and other cell-autonomous immune functions, such as 
the proteasome, could be activated to protect the neuron.  
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5. Concluding remarks and future 
perspectives 
 The symptoms and sequelae of HSE and other alphaherpesvirus CNS 
infections have been well described in the literature. However, less is known of 
how the virus enters the CNS and finds its way to the specific locations where the 
infection is seen in MRI or CT scan. This thesis provides two models for studying 
alphaherpesvirus CNS infections – one rat model for spread of the virus in HSE, 
where a previously unreported route – through the AC – for transportation of 
HSV-1 has been suggested, and one stem cell-derived model for infection of cells 
at different stages of differentiation towards cortical neurons. These models may 
be of importance in a research area where accurate models are scarce. 
 CNS infections due to alphaherpesviruses have been demonstrated to be 
complex in their pathogenicity, and brain lesions are most likely caused by a 
combination of viral factors, cell properties and immune activities. No 
pathogenetic factor can be selected as the single most important, but these 
infections may rather arise from a series of unfortunate combinations of events. 
 The importance of the mucin-like region for viral attachment and release from 
cells provides a new target for antiviral treatment, where entry, egress and cell-to-
cell spread of virus can be reduced. Moreover, without a functioning immune 
system, mitotic cells are more vulnerable to infection than are post-mitotic cells 
indicating the contribution of the immune system to the damage in CNS besides 
the actual effect of the viral infection.  
 The results presented in this thesis indicate that the innate immune response 
plays an important role in the acute and late stages of HSE. This implies that 
antiviral treatment alone is not sufficient to treat the CNS infection; a combined 
approach where immunomodulating treatment is used as complementary 
medication might be needed. Further research of prolonged innate immune 
responses in CNS is required, as this treatment approach might be valid, not only 
for HSE but also for other CNS infections with long-lasting sequelae. The findings 
of long-term complement activity in HSE patients can contribute to future 
evolvement in therapy and may influence new treatment recommendations.
 Finally, although viral CNS infections are rare, their severity should not be 
neglected. With the increasing threat of CNS infections caused by arboviruses, 
such as TBE virus, Dengue virus, West Nile virus, and most recently Zika virus, 
the need for appropriate cell and animal models to study these infections, as well 
as methods for evaluating the immune response evoked, is constantly growing. 
Although findings presented in this thesis are related to the pathogenesis of 
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alphaherpesviruses, they can hopefully contribute to future research on other viral 
CNS infections.  
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